

Volume 6, No. 5, September 2016 * Bimonthly

ISSN: 2251-9939

Journal of Life Science and Biomedicine



Available online at www.jlsb.science-line.com

*Published by
Scienceline Publications*



Editorial Team

Editor-in-Chief: Parham Jabbarzadeh Kaboli

PhD of Molecular Biology and Cancer researcher; Faculty of Medicine and Health Sciences, University Putra, Malaysia ([Website](#); [Emails: researchgroups@drugdiscovery.ir](#))

Managing Editor: Yusuf Kaya

PhD, Professor of Biology, Atatürk University, Erzurum, ([Website](#), [Email: ykaya@atauni.edu.tr](#))

Executive Editor: Zohreh Yousefi

PhD candidate, Biosystematics, Atatürk University, Erzurum, Turkey ([Emails: zohreh.yousefi12@ogr.atauni.edu.tr](#))

Language Editor: Samuel Stephen Oldershaw

Master of TESOL, The Humberston School & The Grimsby Institute, Nuns Corner, Grimsby, North East Lincolnshire, United Kingdom ([Email: s.s.oldershaw@hotmail.com](#))

Associate Editors

Aleksandra K. Nowicka

PhD, Pediatrics and Cancer researcher; MD Anderson Cancer Center, Houston, Texas, USA ([Email: aknowicka@mdanderson.org](#))

Paola Roncada

PhD, Pharmacokinetics, Residues of mycotoxins in food and in foodproducing species, University of Bologna, Italy ([Email: paola.roncada@unibo.it](#))

Tohid Vahdatpour

PhD, Assistant Prof., Physiology, Islamic Azad University, Iran ([Website](#); [Scopus](#); [Emails: vahdatpour@iaushab.ac.ir](#))

Veghar Hejazi

MD, Tabriz University of Medical Sciences, Tabriz, Iran ([Email: vegharhejazi@gmail.com](#))

Nefise Kandemir

MD, PhD, Department of Medical Genetics, Erciyes University, Kayseri, Turkey

Reviewers

Abolghasem Yousefi

PhD, Assistant Professor of Anesthesiology, Tehran University of Medical Sciences, Tehran, Iran ([Website](#); [Email: ayousefi@gmail.com](#))

Aleksandra K. Nowicka

PhD, Pediatrics and Cancer researcher; MD Anderson Cancer Center, Houston, Texas, USA ([Email: aknowicka@mdanderson.org](#))

Amany Abdin

PhD, Pharmacology; MSc, Medical Biochemistry; Tanta University, Egypt ([Emails: amanyabdin@med.tanta.edu.eg, amanyahr@hotmail.com](#))

Babak yousefi

Physician, General Surgery Resident at Hamedan University of Medical Science, Hamedan, Iran

Fazal Shirazi

PhD, Infectious Disease researcher at MD Anderson Cancer Center, Houston, Texas, USA

Fikret Çelebi

Professor of Veterinary Physiology; Atatürk University, Turkey ([Website](#); [Email: fncelebi@atauni.edu.tr](#))

Ghada Khalil Al Tajir

PhD, Pharmacology, Faculty of Medicine, UAE University, Al Ain, UAE

M.R. Ghavamnasiri

PhD, Professor of Oncology at Omid Cancer Hospital, MUMS; Cancer Research Center, Mashhad University of Medical Sciences, Iran

Kaviarasan Thanamegm

PhD of Marine Bioactive compounds, Department of Ecology and Environmental Sciences, Pondicherry University, India ([Email: marinekavi@gmail.com](mailto:marinekavi@gmail.com))

Jahan Ara Khanam

PhD, Anti-cancer Drug Designer and Professor of UR; Department of Biochemistry and Molecular Biology, University of Rajshahi, Bangladesh

Mozafar Bagherzadeh Homaee

PhD, Plant Physiology, University of Isfahan, Isfahan, Iran

Osman Erganiş

Professor, PhD, Veterinary Microbiology, Selcuk University, Konya, Turkey

Paola Roncada

PhD, Pharmacokinetics, Residues of mycotoxins in food and in foodproducing species, University of Bologna, Italy ([Email: paola.roncada@unibo.it](mailto:paola.roncada@unibo.it))

Perumal Karthick

Professor, PhD, Marine Biology, Pondicherry University, Brookshabad Campus, Port Blair, Andamans. 744112, India ([Email: karthickmicrobes@gmail.com](mailto:karthickmicrobes@gmail.com))

Reza Khodarahmi

PhD, Biochemistry at KU; Pharmacy School, Kermanshah University, Kermanshah, Iran

Saeid Chekani Azar

PhD, Veterinary Physiology, Atatürk University, Erzurum, Turkey ([Google Scholar](https://scholar.google.com/citations?user=saeid.azar); [Emails: saeid.azar@atauni.edu.tr](mailto:saeid.azar@atauni.edu.tr); schekani@gmail.com)

Siamk Sandoughchian

PhD Student, Immunology, Juntendo University, Japan

Siva Sankar. R.

PhD, Marine Biology, Dept. of Ecology & Environmental Sciences, Pondicherry University, Puducherry - 605014, India ([Email: sivauniverse@gmail.com](mailto:sivauniverse@gmail.com))

Tohid Vahdatpour

PhD, Assistant Prof., Physiology, Islamic Azad University, Iran ([Website](#); [Scopus](#); [Google Scholar](#); [Emails: vahdatpour@iaushab.ac.ir](mailto:vahdatpour@iaushab.ac.ir))

Veghar Hejazi

MD, Tabriz University of Medical Sciences, Tabriz, Iran ([Email: vegharhejazi@gmail.com](mailto:vegharhejazi@gmail.com))

Yusuf Kaya

PhD, Professor of Plant Biology, Atatürk University, Erzurum, Turkey ([Email: ykaya@atauni.edu.tr](mailto:ykaya@atauni.edu.tr))

Volume 6 (5); September 25, 2016

Research Paper

Screening of Novel Angiotensin I Converting Enzyme Inhibitory Peptides Derived From Enzymatic Hydrolysis of Salmon Protamine.


Rasyad F, Huang TC, Hsu JL, Fadjar M.
J. Life Sci. Biomed., 6 (5): 100-105, 2016;
 pii:S225199391600017-6

Abstract

Angiotensin I converting enzyme (ACE) inhibitory peptide is widely recognized as useful therapeutic approach in the treatment of hypertension. Bioactive peptides from natural sources, including marine fish, are more considered because it has no harm effects. The objective of this study is screening the presence of potential ACE inhibitory peptide from salmon protamine. ACE inhibitory peptide was purified from salmon protamine after 16 hours of hydrolysis by various enzymes and centrifuged using 3 kDa molecular weight cut off (MWCO) ultrafiltration membrane. The peptide sequences were analyzed by Liquid Chromatography Tandem Mass Spectrometric (LC-MS/MS). ACE inhibitory activity was measured using Reversed-Phase High-Performance Liquid Chromatography (RP-HPLC). The results indicated that trypsin hydrolysate had the highest ACE inhibitory activity compared to the other hydrolysates with IC₅₀ value 135.96 µg/ml. LC-MS/MS analysis of tryptic protamine identified two major peaks with three peptide sequences, Ser-Ser-Arg-Pro-Ile-Arg (SR-6), Ser-Ser-Ser-Arg-Pro-Ile-Arg (SR-7), Pro-Arg-Arg-Ala-Ser-Arg (PR-6) which sourced from salmine of Chum Salmon (*Oncorhynchus keta*). The ACE inhibitory peptides from Salmon Protamine still has not been reported previously, therefore it can be beneficial for preventing hypertension.

Keywords: Angiotensin I Converting Enzyme (ACE), Antihypertensive, Bioactive Peptide, Chum Salmon (*Oncorhynchus keta*), Enzymatic hydrolysate, Salmon Protamine

[Full text-[PDF](#)] [[XML](#)]



Review

On the Physiology and Medicine of Aging.


Pandit A, Pandey Bahuguna D, Kumar Pandey A, Pandey BL.
J. Life Sci. Biomed., 6 (5): 106-114, 2016;
 pii:S225199391600018-6

Abstract

World-over the population of aged is steadily increasing and physiology and medicine of aging constitute major biomedical concern. Evolutionary understanding of biology has given rise to multiple diverse causal theories of aging, with different extents of scientific validation. Genetic coding of life span has not been tenable, although the gene-environment interactions seem to heavily bear upon the phenomenon. Visibly, aging involves structural and functional erosion undermining efficient bodily readjustments to the demands of changing life environments. Age associated diseases indicate imbalance in energy intake and expenditure. Healthy process of ageing must be impacted by the same to acquire undesirable forms and rate of progression. Aberrations in lifestyle and nutrition prominently link to pathogenesis of age associated diseases, and provide objects for preventive and corrective interventions. Treading on such very frame, the physiologic and medical understanding of the ageing process, is herein, developed with a degree of over-simplification. The current understanding on biological factors of aging is reviewed emphasizing the interrelation among them, to contemplate personalized preventive and mitigative interventions.

Keywords: Biology of ageing; Physiology of ageing; Mechanisms of ageing; Ageing prevention; Medical management of ageing.


[Full text-[PDF](#)] [[XML](#)]



Results of Gastroesophageal Collector Modified Total Dissociation in Patients with Portal Hypertension.

Nazyrov FG, Devyatov AV, Babadjanov AKh and Ruziboev SA.

J. Life Sci. Biomed., 6 (5): 115-119, 2016;
pii:S225199391600019-6

**Abstract**

The purpose of research was to study long-term results of the modified technique of gastroesophageal collector total dissociation (GECTD) in patients with portal hypertension. Materials and methods. Currently a modified version of the operation has been performed in 73 patients with the portal hypertension (PH) syndrome. In 36 patients the cause of PH was liver cirrhosis, 30 patients were diagnosed with extrahepatic form of PH, mixed form of PH was determined in 8 patients. The age of patients ranged from 13 to 65 years, thus the median was 31.6 ± 1.7 years. Patients randomizing by gender was as follows: men - 44, women - 29. In 53 cases patients were admitted in a planned order, and 20 patients were delivered urgently with the clinical picture of gastroesophageal bleeding. Results and discussion remote period was followed up in 46 patients with primary procedure and in 66 patients with a modified technique of GECTD. Rebleeding was observed in 15.2% of patients, 6.5% on the background of anastomosis. Gastrostasis occurrence was detected in 3 of 46 patients. Liver failure occurred in 23.9% of patients, 15.2% patients died on the background of these complications. In the group with a modified procedure bleeding was observed in 6.0% cases. Bleedings from erosion in the area of ligature transection were stopped conservatively. Mortality in long-term period of observation was 7.6% (5 patients). Overall mortality for the near and distant periods in the comparison groups was 22.2% and 16.4%, respectively. Conclusion – dissociation of gastroesophageal venous reservoir by ligature transection on synthetic prosthesis, unlike previously proposed methods of GECTD allows not only to ease technique of operation, but also provides prevention of early postoperative complications associated with traumatism of previous methods, as well as the stomach gross functional disorders in the long term period.

Keywords: Liver Cirrhosis, Portal Hypertension, Dissociative Operations, Technique of Ligature Transection, Bleeding from Esophageal Varices

[Full text-[PDF](#)] [[XML](#)]

[Archive](#)

Journal of Life Science and Biomedicine



ISSN: 2251-9939

Frequency: Bimonthly

Current Issue: 2016, Vol: 6, Issue 5 (September)

Publisher: [SCIENCELINE](http://www.science-line.com)

The Journal of Life Science and Biomedicine is aimed to improve the quality and standard of life with emphasis on the related branches of science such as biology, physiology, biochemistry, zoology, anatomy, pathology and their applications and innovations in medicine and healthcare... [view full aims and scope](#)

<http://jlsb.science-line.com>

» JLSB indexed/covered by [NLM Catalog](#), [RiCEST \(ISC\)](#), [Ulrich's™](#), [SHERPA/RoMEO](#), [Genamics](#), [Google Scholar \(h-index= 10\)](#), [Index Copernicus](#), [ICV2015: 66.26... details](#)

» Open access full-text articles is available beginning with Volume 1, Issue 1.

» Full texts and XML articles are available in ISC-RiCEST.

» This journal is in compliance with [Budapest Open Access Initiative](#) and [International Committee of Medical Journal Editors' Recommendations](#).



» High visibility of articles over the internet.

» Publisher Item Identifier [...details](#)

» This journal encourage the academic institutions in low-income countries to publish high quality scientific results, free of charges... [view Review/Decisions/Processing/Policy](#)



[ABOUT US](#)

| [CONTACT US](#)

| [PRIVACY POLICY](#)

Editorial Offices:

Atatürk University, Erzurum 25100, Turkey

University of Manitoba, Winnipeg, Manitoba R3T 2N2, Canada

University of Maragheh, East Azerbaijan, Maragheh 55136, Iran

Homepage: www.science-line.com

Phone: +98 914 420 7713 (Iran); +90 538 770 8824 (Turkey); +1 204 8982464 (Canada)

Emails:

administrator@science-line.com

saeid.azar@atauni.edu.tr



Screening of Novel Angiotensin I Converting Enzyme Inhibitory Peptides Derived From Enzymatic Hydrolysis of Salmon Protamine

Fikriyah Rasyad^{1,2}, Tzou-Chi Huang², Jue-Liang Hsu², Mohamad Fadjjar¹

¹ Department of Aquaculture, University of Brawijaya, Indonesia

² Department of Biological Science and Technology, National Pingtung University of Science and Technology, Taiwan

✉ Corresponding author's Email: fikriyah.rasyad@gmail.com

Received 05 Aug. 2016; Accepted 07 Sep. 2016

ABSTRACT: Angiotensin I converting enzyme (ACE) inhibitory peptide is widely recognized as useful therapeutic approach in the treatment of hypertension. Bioactive peptides from natural sources, including marine fish, are more considered because it has no harm effects. The objective of this study is screening the presence of potential ACE inhibitory peptide from salmon protamine. ACE inhibitory peptide was purified from salmon protamine after 16 hours of hydrolysis by various enzymes and centrifuged using 3 kDa molecular weight cut off (MWCO) ultrafiltration membrane. The peptide sequences were analyzed by Liquid Chromatography Tandem Mass Spectrometric (LC-MS/MS). ACE inhibitory activity was measured using Reversed-Phase High-Performance Liquid Chromatography (RP-HPLC). The results indicated that trypsin hydrolysate had the highest ACE inhibitory activity compared to the other hydrolysates with IC₅₀ value 135.96 µg/ml. LC-MS/MS analysis of tryptic protamine identified two major peaks with three peptide sequences, Ser-Ser-Arg-Pro-Ile-Arg (SR-6), Ser-Ser-Ser-Arg-Pro-Ile-Arg (SR-7), Pro-Arg-Arg-Ala-Ser-Arg (PR-6) which sourced from salmine of Chum Salmon (*Oncorhynchus keta*). The ACE inhibitory peptides from Salmon Protamine still has not been reported previously, therefore it can be beneficial for preventing hypertension.

Author Keywords: Angiotensin I Converting Enzyme (ACE), Antihypertensive, Bioactive Peptide, Chum Salmon (*Oncorhynchus keta*), Enzymatic hydrolysate, Salmon Protamine

ORIGINAL ARTICLE
Pli: S225199391600017-6

INTRODUCTION

Nowadays, the inhibition of ACE activity is commonly known as a functional therapeutic agent for preventing and curing hypertension. It has been in use for the last two decades and the tendency to use them will be continuously increased [1]. Currently, several synthetic antihypertensive drugs based on ACE inhibitors have been clinically used such as captopril, enalapril, alacepril, and lisinopril [2]. Even though these synthetic ACE inhibitors could be possibly utilized as antihypertensive drugs, unfortunately they still have some undesirable side effects such as coughing, allergic reactions, taste disturbance, and skin rashes [3]. Thus, developments and investigations to explore a beneficial and economical ACE inhibitors are required to prevent hypertension.

One of the most popular and favorite fish in the world is Salmon. It is considered to be healthy due to its high nutritional value and pharmacological activity. Previous studies have investigated ACE inhibitory peptides from Salmon by-product such as fillet and residuals [4], skin [5, 6], and pectoral fin [7]. However, the ACE inhibitory peptides from Salmon Protamine still has not been reported.

The objectives of this study were to hydrolysis protein using different proteases, and the protein hydrolysate was assessed for bioactivity including angiotensin converting enzyme (ACE) inhibitory activity. Furthermore, the sequences of the bioactive peptides were determined by LC-MS/MS [8].

MATERIALS AND METHODS

Salmon Protamine were treated with a single protease, with an enzyme to protein ratio of 1:50 (w/w) using different temperatures which were based on the enzymes' activities: trypsin (37 °C), α -chymotrypsin (37 °C), pepsin (37 °C), and thermolysin (60 °C). The enzymatic digestions of the salmon protamine were kept at pH 8, except for pepsin, which was adjusted to pH 1.3. After incubation for 16 hours, the hydrolysis was stopped by centrifugation at low temperature (14,000 rpm, 10 min, 4 °C) in ultrafiltration membrane (3 kDa MWCO). The filtrate (<3 kDa) was lyophilized and kept at -20 °C for further assay or analysis.

The ACE inhibitory activity was determined according to the method reported by Cushman et al [9] with partial modification. The sample solution containing 30 μ l of 2.5 mM hippuryl-L-histidyl-L-leucine (HHL) as a substrate and 10 μ l of inhibitor (at an indicated concentration) in 200 mM borate buffer containing 300 mM NaCl (adjusted to pH 8.3) was pre-incubated at 37 °C for 5 minutes. The control solution was prepared using the same buffer but without inhibitor. Afterwards, 20 μ l of 2 mU/ml ACE in 200 mM borate buffer was added to the sample solution and control solution, individually. The reaction mixture was incubated statically at 37 °C for 30 minutes and then shaken in a thermostatically controlled shaker incubator (200 rpm) at 37 °C for 30 minutes. The reaction was quenched under acidic conditions by adding 1 M HCl (60 μ l). Ferulic acid 0.2 mg/ml (10 μ l) was used as an internal standard for normalizing variation derived from different samples. HHL and its hydrolyzed product, hippuric acid (HA) were analyzed using an HPLC equipped with a C₁₈ column. The resulting HA was detected using a UV detector fixed at 228 nm. The ACE inhibition (%) was determined based on the following equation:

$$[1 - (\Delta A_{\text{inhibitor}} / \Delta A_{\text{control}})] \times 100$$

where $\Delta A_{\text{inhibitor}}$ was the peak area of HA in the reaction mixture by the presence of peptide as ACE inhibitor and $\Delta A_{\text{control}}$ was the peak area of HA in the reaction mixtures without peptide as ACE inhibitor. Definition of ACE activity: One unit (U) of ACE activity was defined as the amount of enzyme required to catalyze formation of 1 μ mol of HA from HHL per minute at 37 °C.

The peptide sequences in the lyophilized hydrolysate were further identified using LC-MS/MS analysis and database matching. Freeze dried peptides were dissolved in 5% ACN (Acetonitrile) and 0.2% FA (Ferulic acid) in deionized water for LC-MS/MS analysis. LC-MS/MS analysis was performed using a Thermo LCQ DECA XP MAX system with an electrospray ionization (ESI) source (Thermo Scientific Inc., USA). Samples were loaded onto a BioBasic C₁₈ column with diameter 150 \times 2.1 mm, particle size 5 μ m. The mobile phase consisted of Solution A (100% deionized water and 0.1% FA) and Solution B (100% ACN and 0.1% FA) and was kept at a flow rate of 200 μ l/min. The MS/MS raw data were acquired using Thermo-XCalibur™ (Thermo-Scientific) then processed into MGF files using Mascot Distiller v2.3.2.0 (Matrix Science, London, UK). The resulting MGF files were searched using the Mascot search engine v2.3 (Matrix Science, UK).

RESULTS AND DISCUSSIONS

ACE inhibitory activity of each hydrolysates is shown in Figure 1. Captopril is used as positive control. All hydrolysates have potential to inhibit ACE, but compared to other hydrolysates, the highest inhibition was shown in tryptic hydrolysate with 94.82% followed by chymotrypsin, thermolysin and pepsin with the inhibition of 79.11%, 70.20%, 48.66% respectively.

Tryptic hydrolysate, because it has the highest ACE inhibition, further was analyzed for IC₅₀ of ACE inhibition activity. The IC₅₀ or the half maximal inhibitory concentration represents the concentration of a peptide that is required for 50% inhibition of its target enzyme. To find out the IC₅₀ value of crude hydrolysates, the relative ACE inhibition was first determined for various concentrations of peptide; afterwards, the IC₅₀ was evaluated by plotting the curves of relative ACE inhibition against six different peptide concentrations (Figure 2).

The IC₅₀ value of tryptic hydrolysate was considered as a low inhibition. The low IC₅₀ value may be due to cumulative and synergistic effects of various active peptides present in each hydrolysate [10].

To characterize the peptide identities, the lyophilized tryptic hydrolysate was subjected into LC-MS/MS for analysis of ACE inhibitory peptides. Two major peaks were observed in the LC-MS chromatogram. Through LC-MS/MS analysis and database-assisted identification, peptides derived from Salmon Protamine are compared to the predicted peptides forecasted by peptide sequence application. All the sequences are summarized in Table 1.

LC-MS/MS analysis indicated two major peaks with three peptide sequences. A peptide was located at the first peak with retention time at minute 1.74, whereas two other peptides were located at the second peak with retention time at minute 10.70 and 10.95 respectively. Based on Mascot Distiller database search, for triply

charged the peptide with m/z at 247.91 was identified as Pro-Arg-Arg-Ala-Ser-Arg (PRRASR), for doubly charged the peptide with m/z at 358.60 as Ser-Ser-Arg-Pro-Ile-Arg (SSRPIR) and m/z at 402.03 as Ser-Ser-Ser-Arg-Pro-Ile-Arg (SSSRPIR).




Figure 1. ACE inhibitory activities of enzymatic hydrolysates from Salmon Protamine.




Figure 2. IC₅₀ of tryptic hydrolysate from salmon protamine.

Table 1. Comparison of tryptic hydrolysate and predicted tryptic peptide sequences.

Tryptic Hydrolysate Peptides			Predicted Tryptic Peptides		
m/z	Position	Sequence	m/z	Position	Sequence
802.0454	6-12	SSSRPIR	802.4530	6-12	SSSRPIR
715.1854	7-12	SSRPIR	428.2728	15-17	RPR
740.9328	16-21	PRRASR	333.1881	19-21	ASR




Figure 3. LC-MS chromatogram of tryptic hydrolysate




Figure 4. LC-MS chromatogram of peptide SSSRPIR




Figure 5. Mass spectrum of peptide with m/z 402.03 for doubly charged and m/z 802.42 for singly charged.

Recently, salmon protamine widely used for pharmaceutical excipients. This cationic peptide derived from salmon milt. Protamine itself has a molecular mass of approximately 4000 Da with about 70% of the basic amino acid arginine. Basically, protamines belong to a diverse protein family of arginine rich peptides. Peptides derived from protamine could be useful to observe the differential *in vitro* antimicrobial activity of a 12-residue-long arginine-rich peptide and examined against bacterial and parasite microbes. Protamine C-terminal fragment can be utilized as a potential new antimicrobial peptide [11].

In addition to medical and antimicrobial use, Salmon Protamine is also expected could be used as antihypertensive agent. Higher level of arginine can be investigated for hypertension therapy. Since the arginine-rich peptides also exhibited moderate *in vitro* ACE and renin inhibitory activities, it is also possible that more than one mechanism was involved in producing the antihypertensive effects [12].

Digestion of salmon protamine by various digestive enzymes has resulted the release of bioactive peptides. Chymotrypsin, pepsin, thermolysin and trypsin are some of commonly used and widely distributed commercial enzymes. According to the result of this research, tryptic hydrolysate of salmon protamine has the highest ACE inhibitory activity. It indicated that bioactive peptides hydrolysis strongly affected by protease. Trypsin is widely used to produce ACE inhibitory peptides. However, other proteinases (chymotrypsin, pepsin, thermolysin) as well as enzymes from bacterial and fungal sources have been utilized to generate bioactive peptides [13].

CONCLUSION

Angiotensin I Converting Enzyme (ACE) Inhibitory peptides were screened from enzymatic hydrolysis of salmon protamine using various enzymes. Tryptic hydrolysate has the highest ACE inhibitory activity. LC-MS/MS analysis of tryptic protamine identified two major peaks with three peptide sequences, Ser-Ser-Arg-Pro-Ile-Arg (SR-6), Ser-Ser-Ser-Arg-Pro-Ile-Arg (SR-7), Pro-Arg-Arg-Ala-Ser-Arg (PR-6) which sourced from salmine AII of Chum Salmon (*Oncorhynchus keta*). According to this study, it can be concluded that bioactive peptide derived from salmon protamine has a potential ACE inhibitory peptide. Further study of ACE inhibitory peptide from Salmon protamine and the antihypertensive effect on spontaneous hypertensive rat (SHR) is highly needed in order to discover a new innovation in the treatment of hypertension.

Competing interests

The authors declare that they have no competing interests.

REFERENCES

1. Pfeffer MA and Frohlich ED. 2006. Improvements in clinical outcomes with the use of angiotensin-converting enzyme inhibitors: cross-fertilization between clinical and basic investigation. *American Journal of Physiology, Heart and Circulatory Physiology*. 291: H2021-2025.
2. Wijesekara I and Kim SK. 2010. Angiotensin-I-Converting Enzyme (ACE) Inhibitors from Marine Resources: Prospects in the Pharmaceutical Industry. *Marine Drugs*. 8: 1080–1093.
3. Atkinson AB and Robertson JL. 1979. Captopril in the treatment of clinical hypertension and cardiac failure. *Lancet* (London, England). 2: 836–839.
4. Dragnes BT, Stormo SK, Larsen R, Ernsten HH and Elvevoll EO. 2009. Utilisation of fish industry residuals: Screening the taurine concentration and angiotensin converting enzyme inhibition potential in cod and salmon. *Journal of Food Composition and Analysis*. 22: 714–717.
5. Gu RZ, Li CY, Liu WY, Yi WX and Cai MY. 2011. Angiotensin I-converting enzyme inhibitory activity of low-molecular-weight peptides from Atlantic salmon (*Salmo salar* L.) skin. *Food Research International*. 44:1536–1540.
6. Lee JK, Jeon JK, Byun HG. 2014. Antihypertensive effect of novel angiotensin I converting enzyme inhibitory peptide from chum salmon (*Oncorhynchus keta*) skin in spontaneously hypertensive rats. *Journal of Functional Foods*. 7: 381–389.
7. Ahn CB, Jeon YJ, Kim YT and Je JY. 2012. Angiotensin I converting enzyme (ACE) inhibitory peptides from salmon byproduct protein hydrolysate by Alcalase hydrolysis. *Process Biochemistry*. 47: 2240–2245.
8. Sunantha K and Saroot R. 2013. Purification and characterization of ace inhibitory peptide from aquatic resources: Review Sunantha Ketnawa and Saroot Rawdkuen Program of Food Technology , School of Agro-Industry, Mae Fah Luang University, To whom correspondence shou. *International Journal of Plant, Animal and Environmental Sciences*. 3: 220–233.
9. Ondetti MA, Rubin B and Cushman DW. 1977. Design of specific inhibitors of angiotensin-converting enzyme: new class of orally active antihypertensive agents. *Science*. 196: 441–444.
10. Salampessy J, Reddy N, Kailasapathy K and Phillips M. 2015. Functional and potential therapeutic ACE-inhibitory peptides derived from bromelain hydrolysis of trevally proteins. *Journal of Functional Foods*. 4:716–725.
11. Lesmes LP, Bohorquez MY, Carreño LF, Patarroyo ME and Lozano JM. 2009. A C-terminal cationic fragment derived from an arginine-rich peptide exhibits in vitro antibacterial and anti-plasmodial activities governed by its secondary structure properties. *Peptides*. 30: 2150–2160.
12. Udenigwe CC and Mohan A. 2014. Mechanisms of food protein-derived antihypertensive peptides other than ACE inhibition. *Journal of Functional Foods*. 8:45–52.
13. Ambigaipalan P, Al-Khalifa AS and Shahidi F. 2015. Antioxidant and angiotensin I converting enzyme (ACE) inhibitory activities of date seed protein hydrolysates prepared using Alcalase, Flavourzyme and Thermolysin. *Journal of Functional Foods*. 18: 1125-1137

On the Physiology and Medicine of Aging

Abha Pandit¹, Deepti Pandey Bahuguna², Abhay Kumar Pandey³✉, Bajrangprasad L. Pandey⁴

¹ Department of Medicine, Index Medical College Hospital and Research Centre, Indore, Madhya Pradesh, India

² Consultant, Otorhinolaryngologist, Shri Laxminarayan Marwari Multispecialty Charity Hospital, Varanasi, Uttar Pradesh, India

³ Department of Physiology, Government Medical College, Banda, Uttar Pradesh, India

⁴ Department of Pharmacology, Institute of Medical Sciences, BHU, Varanasi, Uttar Pradesh, India

✉Corresponding author's Email: drabhaypphysiol@gmail.com; Phone [M]: +91-7607980255

Received 18 Aug. 2016; Accepted 15 Sep. 2016

ABSTRACT: World-over the population of aged is steadily increasing and physiology and medicine of aging constitute major biomedical concern. Evolutionary understanding of biology has given rise to multiple diverse causal theories of aging, with different extents of scientific validation. Genetic coding of life span has not been tenable, although the gene-environment interactions seem to heavily bear upon the phenomenon. Visibly, aging involves structural and functional erosion undermining efficient bodily readjustments to the demands of changing life environments. Age associated diseases indicate imbalance in energy intake and expenditure. Healthy process of ageing must be impacted by the same to acquire undesirable forms and rate of progression. Aberrations in lifestyle and nutrition prominently link to pathogenesis of age associated diseases, and provide objects for preventive and corrective interventions. Treading on such very frame, the physiologic and medical understanding of the ageing process, is herein, developed with a degree of over-simplification. The current understanding on biological factors of aging is reviewed emphasizing the interrelation among them, to contemplate personalized preventive and mitigative interventions.

Author Keywords: Biology of ageing; Physiology of ageing; Mechanisms of ageing; Ageing prevention; Medical management of ageing.

PII: S225199391600018-6

REVIEW

INTRODUCTION

Aging is inevitable phenomenon of biology, driven by multiple factors at varied rates and fashion in different species and even among members of same species. As per the Darwinian principle, successful attainment of reproductive age is minimum essential life span for species [1]. Extended living beyond essential life span results in accumulating damages in biochemical architecture of body comprised of nucleic acids, proteins and lipids. A progressive failure of homeostasis and homeodynamics manifests at different levels of functional organization, worsening in to disease forms and may cause eventual death. The failures of repair and maintenance mechanisms are central to mechanistic principle of aging [2].

Genes and Aging

Finite genetic basis for aging is unconceivable. Consensus is evolving over crucial contribution of threshold changes in epigenetic mechanisms to aging process and absence of any evolving superior repair mechanisms to avert aging. Aging studies in the centenarians, suggest role of human leukocyte antigen (HLA), alleles on specific chromosome loci and also of varied alleles of APOA and APOB genes coding for apolipoproteins A and B, and angiotensin converting enzyme genotype in conferring longevity [3]. Discovery of Klotho (KL) gene encoding α -klotho protein, has helped advancing understanding of ageing process. α -klotho protein is multifunctional and regulates metabolism of phosphates, calcium and vitamin D. Mutation of KL gene are associated with hypertension and kidney disease suggesting renal function as their prime target. In mice, klotho gene functions as ageing suppressor gene, extending life span upon over-expression and to cause accelerated ageing phenotype, when disrupted [4]. α -klotho protein antagonizes a bone derived hormone that inhibits renal vitamin D3 biosynthesis, also suppress insulin and Wnt signaling pathways, inhibits oxidative stress and regulates phosphate and calcium absorption [5]. These proteins locate on renal tubule cell membrane and shed fragments in

circulation. The later interact with signaling pathways of multiple growth viz. insulin/ insulin like growth factor 1(IGF1), Wnt etc. and activity of several ion channels. The protein appears to also protect cells from oxidative stress [6]. Humanin is a mitochondria associated peptide that plays role in cell metabolism, survival, response to stress, inflammation and apoptosis. Humanin analogues favourably influence age related diseases. Association between human in levels and growth hormone/IGF1 axis and life span has also been demonstrated in mice [7].

Developmental ontogeny of organisms is programmed and co-ordinated by genes. No genes have been attributed deterministic role in survival span and genes never evolve to cause disadvantage to the organism [8]. Gene repair capacity is under both genetic as well as epigenetic control which does influence rate of aging. When genes encoding for molecules toward sustaining homeodynamics and homeostasis, cumulate damage and dysfunction, they become “virtual gerontogenes”. Accumulating damages in form of mutations, epimutations, oxidation and aggregation of macromolecules are detrimental to longevity. Certain mutations accelerate aging changes, e.g. through altering insulin sensitivity and metabolism or dynamics of kinases, transcription factors and variety of biological pathways. Altered gene regulation, accumulation of somatic mutations, protein errors and modifications, imbalance of reactive oxygen species and free radicals, immune system deregulation and neuroendocrine dysfunction are involved in systemic homeodynamic failure. At the cellular level shortening of telomeres (the repeat neucleotide containing noncoding DNA at chromosomal ends that protect loss of important DNA), progressive demethylation in the DNA and consequent progressive compromise of renewal and repair system of cells are appealing mechanisms of aging.

Telomeres are DNA protein structures that form protective caps at ends of chromosomes providing safeguard from degradation and maintain genomic integrity. Telomerase enzyme adds DNA sequence repeats in telomere region at the end of chromosomes. Telomeres shorten with each cell division as process of aging. Accelerated loss of telomeres associates chronic age related diseases. Oxidative stress increases erosion of telomere length by oxidative modification of guanine in DNA at each cell division cycle in exposed cells. Shorter telomere length associates increase of body mass index and adiposity and age related pathologies [9]. While adiponectin correlates to longevity [10], disruptive leptin function results in metabolic decline and abnormal body fat distribution [11]. Fat plays important role in regulation of energy metabolism and immune responses. These effects are implemented through adipose tissue derived cytokines [12]. Gradual erosion of telomere length proportionately increase genetic instability over the life course. When critically short length is reached, cell stops dividing making no regenerative contribution to systemic maintenance [13].

Pathophysiologic understanding of the aging process

Ongoing biomedical research suggests disturbed rhythm of lifestyle eg., night shifts and stressors, improper and excess eating, physical inactivity as provocative to multifaceted molecular mechanisms hastening the process of ageing. The cellular senescence displays arrested division and threatened survival. Aging organism displays progressive compromise in physiological functions and inability for homeostasis in face of stress, with increased risk of age related diseases. Many aspects of physiology and behavior are driven by intrinsic circadian rhythm which keeps synchrony among varied biological processes of the organism and co-ordinates them with the environment. Components of the biological clock are also crucially involved in modulating physiological response to genotoxic stress (specially, the oxidative stress), regulation of cell cycle, other proageing mechanisms, carcinogenesis etc. Components of energy homeostasis, notably in the adipocytes, exhibit circadian rhythm in energy balance, feeding behavior and regulation of body weight [14]. Dysegregation of glucose and lipid metabolism, insulin sensitivity, detoxification of xenobiotics, and such other activities in varied permutations and combination, aggravating ageing changes [15]. Psychological stress denotes overwhelming demand for constant adjustments to changing environment and its molecular consequences (e.g. stress hormones, insulin sensitivity, oxidative stress, inflammation, etc.). It links to unhealthy aging process [16, 17].

Negative effects of major stress on health are well documented. The aspects of stress-resistance however, have potential to guide strategies for delaying ageing, especially at cellular level. Exposure to short term stress may strengthen cellular adaptive response to stress (hormetic stress) with enhanced activity of molecular chaperones and other defensive mechanisms. Prolonged exposure to stress, on the contrary, may overwhelm compensatory responses [18].

Ageing process: as mTOR driven

Among the earliest theories of ageing being driven by oxidative stress, presupposes intracellular nutrient and energy status as under constant scrutiny including, functional state of mitochondria and concentration of reactive oxygen species produced in them and co-ordinated flow of such information along diverse multiple

signaling pathways subserves regulation of life span. The concept now prevalent is that ageing is not simple result of molecular damage (nor by free radicals), but results from a purposeless quasi programme (programme like but not a programme), partly driven by TOR (target of rapamycin). TOR in eukaryotic cells is a conserved member of phosphatidylinositol kinase-related kinases family. In the mammals rapamycin sensitive is the mTOR Complex 1mTORC1. mTOR signaling pathway is master regulator of cell growth and metabolism [19]. The quasi-programmed phenomenon of ageing is driven by the over reaction of the crucial nutrient sensing mTOR (mammalian target of rapamycin) gero-gene. mTOR driven ageing may be triggered or accelerated by decline or loss of responsiveness to activation of another energy sensing protein AMPK (AMP Kinase). AMPK is a critical gero-suppressor of mTOR. The age related infirmity, therefore reflects synergistic interaction with our evolutionary path to sedentarism. Physical inactivity chronically increases a number of mTOR activating gero-promoters (e.g. Food, growth factors, cytokines, insulin). These lead to defective design of central metabolic integrators such as mTOR and AMPK [20]. mTOR kinase integrates signals from nutrients, energy status, growth factors and a variety of stressors. It then affects rate of protein synthesis and degradation via autophagy, through number of downstream effects [21]. mTOR mediates the switch between growth and somatic stability to extend lifespan.

Nutrients (glucose, amino acids, especially leucine) and fatty acids directly activate the mTOR pathway and also increase insulin levels, which can additionally activate mTOR [22]. Modulation of mTOR signaling network affects mRNA translation, transcription, autophagy, ribosomal biogenesis, metabolism and cell survival, proliferation, cell size and growth, endoplasmic reticulum stress signaling and other stress responses [23]. Constitutively active TORC1 augments overall protein synthesis by increasing the speed of ribosomal elongation along transcripts. Such elongation induces different extents of translational errors with wrong incorporation of amino acids and defective folding of polypeptides, resulting in failure of protein quality control [24]. Rapamycin can inhibit TORC1 and inhibit translational activity. This will reduce waste-full formation of rough proteins during cell division that can impair lifespan of non-dividing cells. Rapamycin inhibitory effect is mediated via ribosomal S6Kinases.

Hyperfunction theory of ageing postulates that proximal cause of ageing is not the accumulation of random molecular damage, but overactive cellular functions (25). The nutrient sensing TORC1 signalling pathway seems to be a key contributor. Its inhibition by drugs or dietary restriction reduces translation, apparently allowing for better protein quality control. Accumulation of protein misfolding is thus reduced, which would otherwise cause age related pathologies. Reduced protein translation has been linked to increased life span [26].

Inhibition of mTOR is major way to maintain proteome and manage energy through the aging process. When cell energy content falls, that activates AMPK. AMPK directly phosphorylates TSC2 (Tuberous Sclerosis Complex 2), a negative regulator of mTORC1 and Raptor, an essential binding partner for induction of translation by mTORC1, resulting in inhibition of later activity. The mTORC1, S6K and AMPK constitute a complex feedback loop that is sensitive to dietary restriction and can redirect growth, metabolism and lifespan. Besides nutrients and growth factors, inputs about environmental stressors also influence control of growth. Osmotic stress, hypoxia, endoplasmic reticulum(ER), stress, genotoxic stress, mechanical forces and contraction (muscle movement) may all regulate mTORC1 activity. The growth hormone/insulin like growth factor 1(GH/IGF1), axis is strongly implicated in diet restriction effect. Reduced GH and IGF1 signaling associates with longer lifespan. Dietary Restriction (DR) reduces GH/IGF1 pathway signaling. There is key role of energy efficiency in determining health and longevity. Equally importantly, modulation of mTOR activity mediates proteostasis [27].

Role of GCN2: General Control Non depressible Kinase 2(GCN2 kinase) is another nutrient sensing pathway. It phosphorylates eIF2- α transcription factor following nutrient and other stress. GCN2 has central role in stress management by activating key transcription factors such as ATF4 and NFkB in mammals. This stress induced reprogramming also determines life span [28]. For resource conservation and homeostasis under stress, the typical response is inhibition of protein synthesis with reprogramming of gene expression [29]. Inhibition of protein synthesis is attained through phosphorylation of eIF2- α , the translation initiator factor 2. GCN2 is the only eIF2- α kinase conserved through evolution that responds to nutrient depletion by regulating amino acid transport and metabolism. Other stressors also activate GCN2. The kinase also regulates lipid metabolism, oxidative stress resistance, feeding behavior, NFkB signaling, synaptic plasticity and memory.

AMPK: The anti-ageing crusader:

Adenosine mono phosphate activated protein kinase AMPK has emerged as key nutrient-sensor, with ability to regulate whole body metabolism. AMPK is activated by fall in cellular ATP or energy status, indicated by

increased AMP/ATP ratio. Upon activation AMPK turns on, catabolic pathways to restore ATP levels. For the short time frame, glycolysis and fatty acid oxidation is promoted. For long time frame mitochondria content of cell and use of mitochondrial substrates as energy source are increased. Mitochondrial fitness is of great interest in ageing, as effective control of mitochondrial biogenesis, metabolism and turnover is crucial for healthy ageing [30].

AMPK activation is generally linked to the stimulation of metabolic responses in order to prevent metabolic and energy crisis, in situations where ATP synthesis is compromised. Such situations can be low nutrient availability and accelerated ATP consumption states, as exercise and fasting. Activated AMPK stimulates catabolic processes to generate ATP and inhibits ATP consuming anabolic processes that are not essential to immediate cell survival. The later include biosynthesis of fatty acids and sterols, cell growth and division. AMPK is final sensor for glucose and lipid metabolism and integrates nutritional and hormonal signals in peripheral tissue and the hypothalamus. It mediates regulation of food intake, body weight and glucose and lipid homeostasis [31].

mTOR/ ULK 1 Regulation

AMPK signaling is major inducer of autophagy associated with the reduction of energy metabolism, autophagy can be activated by several stressors and seems to be associated with stress resistance. AMPK can regulate initiation of autophagosome formation via different signaling mechanisms. mTOR, the conserved serine/threonine protein kinase is potent inhibitor of autophagy. mTOR is involved in the signaling pathways induced by growth factors, abundant nutrients and sufficient energy states. AMPK can inhibit activity of mTOR complex (mTORC1) via two different mechanisms. It may directly phosphorylate a regulatory component of TORC1, Raptor. It may phosphorylate also TSC2 protein which also suppresses mTOR activity [32, 33]. AMPK dissociates mTORC1 from ULK1 complex to positively regulate autophagy indirectly. Directly, AMPK may bind ULK1 complex and phosphorylate it to stimulate autophagy [34].

AMPK opposing effect of Insulin/IGF1 pathway, in respect to longevity

Insulin/IGF1 pathway also activates mTOR kinase and its downstream targets that regulate protein and ribosome synthesis. mTOR is detrimental as it accelerates ageing process by potent inhibition of autophagy. It is yet unsettled, if lifespan extension is conferred through activation of autophagy or by inhibition of other downstream targets of mTOR. A downstream target of insulin/IGF1-mTOR pathway, S6K1 kinase, can repress AMPK signaling. Deletion of S6K1 stimulates AMPK signaling allowing longevity promotion [35]. Insulin /IGF1 signalling associated with growth hormone regulation represents crucial somatotrophic axis in mammals. Kurosu et al. [36] demonstrated that over expression of klotho protein inhibited insulin/IGF1 signaling and increased life span. Functional deficiency of klotho enhanced premature ageing.

Insulin/IGF1 and AMPK signaling pathways are mutually inhibitory. Insulin/IGF1 pathway may inhibit many networking antiageing pathways of AMPK also. AMPK phosphorylates insulin receptor substrate 1 to inhibit insulin/IGF1 signalling [37]. AMPK however seems to enhance insulin/IGF1 signalling if that supports its metabolic function, e.g. glucose uptake, but represses energy consuming pathways.

AMPK activity is key for mitochondrial biogenesis, but declines with age. Another theory of ageing as consequent to decline in mitochondrial biogenesis is thus, promulgated. Multiple endogenous and exogenous factors regulate mitochondrial biogenesis through PPAR-gamma co-activator- 1alpha (PGC 1alpha). Activators of PGC-1alpha include nitric oxide, CREB (AMP response element binding protein) and AMPK. Activation of the AMPK pathway results in inhibition of the mTOR pathway, conferring possible longevity benefit.

Calorie restriction stimulates, while nutritional overload impairs AMPK activity and concurrently induces insulin resistance. New roles of AMPK beyond maintenance of energy metabolism during state of increased consumption have become known [20]. The rate of living theory of ageing emphasized that energy metabolism maintains homeostasis in the organism, whereas excessive energy consumption enhances ageing process. AMPK may co-ordinate preserving mechanisms as autophagy and increased stress resistance of tissue. AMPK upregulates thioredoxin expression to beat oxidative stress, and represses endoplasmic reticulum stress and inflammation. All these are antiageing in effect. AMPK responsiveness declines during ageing process leading to emergence of age related disorders. Age related changes in protein phosphatases may be basis for suppressed AMPK activation in ageing. Low grade inflammation of ageing also prominently impairs AMPK function.

Multiple networking pathways of lifespan regulation

Ageing research reveals several signaling pathways simultaneously engaging for regulating aging and affecting lifespan. They are organized in integrated network, which has positive feedback effect on AMPK activity.

CTRCs (CREB-regulated transcription co-activator 1), are coactivators of CREB mediated gene transcription and are targets of AMPK action. Inhibition of CRTC induced CREB activation is crucial regulator of ageing and longevity.

AMPK and SIRT1 (silent information regulators) signaling pathways are evolutionally conserved energy sensors in cells responding to the increase in cellular AMP and NAD⁺ concentrations respectively [38]. SIRT1 is major regulator of cellular energy metabolism and many components of cell survival, e.g. apoptosis, cell proliferation and inflammation. SIRT1 regulates stress resistance by directly modulating function of FoxO, p53 and NFkB signaling. The activation of AMPK stimulates functional activity of SIRT1 by increasing intracellular NAD⁺ concentration [39].

FoxO axis: the fork head transcription factors are involved in regulation of apoptosis, cell cycle, stress resistance, glucose and lipid metabolism and inflammation. The target genes of AMPK-FoxO3 pathway associated with longevity include those involved in defense against oxidative stress and DNA repair. The FoxO factors are integral to other longevity mechanisms as, inhibition of NFkB and age related inflammation. Stimulation of autophagy occurs both through FoxO and ULK1/mTOR pathways.

FoxO factors and p53 exist in complex interaction networks. p53 is one target protein of AMPK for control of expression as well as transactivation. Arf/p53 pathway activation promotes longevity via increased expression of antioxidant genes and autophagy. Mitochondria are major targets of several p53 actions which foster their integrity.

AMPK activation can inhibit signaling of master regulator transcription factors of inflammation [40]. AMPK-SIRT1-NFkB signaling pathway has major implication in controlling immune function. AMPK can stimulate Nrf2/SKN 1 signalling which acts in concert with the function of AMPK-FoxO3a axis in the generation of oxidation stress resistant phenotype of long lived animals.

Biomedical contemplation on interventions for control of Life span:

Autophagy is process of lysosome dependant intracellular recycling amino acids and energy resource particularly important in stress. Autophagy, insulin/IGF1 signaling, dietary restriction and reduced mitochondrial function, can modulate the proteostatic machinery to maintain stability of proteome. These mechanisms provide targets for therapeutic intervention [41]. Reducing insulin/IGF1 signaling is prime aging regulatory pathway, effected by protection against toxic protein aggregates in models of Alzheimers disease.

Pharmacologically upregulated autophagy increases clearance of toxic intracellular waste and enhanced lifespan. An understanding on regulatory signals of autophagy however bears serious gaps [42]. Deregulation of mTOR pathway is implicated in age associated disorders and mTOR inhibitor rapamycin treatment offers some curb, with scope for developments in multimodal combination regimens [19].

Pathways sensitive to dietary nutrients can be targeted to alter lifespan include, mTOR pathway, AMPK pathway, oxidative stress response through SRN1/Nrf2. Protein quality control through increased autophagy and general (hermetic) stress response.

Benefit of Weight Reduction: Under calorie restriction more body fat is lost influencing factors at interface of metabolism and inflammation [43]. Calorie restriction in aging rat improves carbohydrate metabolism by decreasing visceral fat and increasing insulin sensitivity [44]. Interventions that stimulate metabolism and/or activate white adipose tissue signaling mimick calorie restriction. Rapamycin is approved classical TOR-inhibitory agent with diverse potentials of imparting longevity. mTORC1 plays central role via S6K and 4E BP [45], that leads to decreasing over all translation allowing better fidelity of autophagy and mechanisms degrading misfolded and damaged proteins. Anti-inflammatory effect of rapamycin and role in depletion of small molecules such as endocannabinoids may also be relevant. Many clinically employed compounds, e.g. aspirin, reduce MTORC1 activity and also activate AMPK. Perhexiline, niclosamide, rottlerin and amiodarone also inhibit mTORC1, as does natural product phenylethyl isothiocyanate (in brassicaceae vegetables). Many mTOR inhibitory drugs may target insulin/IGF1 signaling, pathway to increase lifespan.

AMPK Activation:

Mitochondrial dysfunction is an important component of age related diseases, e.g. type 2 diabetes, Alzheimers etc. AMPK acts as an energy sensor of cell and works as key regulator of mitochondrial biogenesis. Number of drugs and hormones directly or indirectly activate AMPK. Therapeutic exploration is however limited to only metformin that activates AMPK and suppresses mTOR, both life extending actions [46]. Many longevity genes are clustered in to nutrient sensing and metabolic adaptation pathways.

Hormetic stress response induction/preconditioning (47)

Adaptation and survival of cells and organism requires ability to sense proteotoxic insults and to co-ordinate protective cellular stress response pathways and chaperone networks related to protein quality control and stability. The toxic effects that stem from the misassembly or aggregation of peptides/proteins in cell are collectively termed proteotoxicity and result in metabolic, degenerative and neoplastic pathologies.

Strong interest lies in discovery of agents capable of inducing beneficial cytoprotective heat shock response and resistance against major stress. Low dose "HORMETIC" stress pathways include signaling mechanisms by which the carnitine system, mitochondrial energetics and activation of critical vitagenes, modulate signal transduction cascades conferring cytoprotection.

Modest free radical stress and lipid peroxidation products induce hermetic stimulation of energy metabolism pathways, mitochondrial biogenesis and upregulation of protein chaperones and antioxidant systems [48].

Protein thiols regulating cellular redox state are crucial mediator of multiple metabolic signaling and transcriptional processes. Pro-survival pathways are activated by vitagenes producing Hsps, glutathione, bilirubin with antioxidant and antiapoptotic property. Drugs capable of inducing Hsp response are of great interest, therefore.

SIRT1 deacetylates and activates transcription regulator PGC1- α that directs adaptive response to caloric restriction and exercise, promoting production of antioxidant and detoxifying enzymes. Heat Shock transcription factor 1 (HSF1) is central regulator of gene expression of Hsps and other vitagenes in electrophile counterattack response (against reactive oxygen species and radicals). The vitagenes expression of this group is regulated by Keilch-like ECH-associated protein 1 Keap1/Nrf2 /ARE (antioxidant response element) pathway [49].

Variety of natural chemicals are inducers of Keap1/Nrf2/ARE pathway. Their common shared property is reactivity with sulfhydryl groups.

Hormetic mechanisms account for health benefits of phytochemicals. They generally activate adaptive cellular response pathways including kinases, and transcription factors that induce the expression of genes encoding antioxidant enzymes, protein chaperones, phase-2 enzymes, neurotrophic factors and other cytoprotective proteins. Sulforaphane (Brassicaceae), curcumin and resveratrol are inducers of Keap1/Nrf2/ARE pathway. Resveratrol also activates Sirtuin/FOXO pathway with increased antioxidant enzymes and survival protein buildup [50]. Other phytochemicals may activate hermetic transcription factors CREB (cyclic AMP response Element Binding protein) leading to induction of genes coding growth factors and antiapoptotic proteins [51].

Carnitine and Acetyl Carnitine: Mitochondrial content of endogenous acetyl carnitine is indicator of mitochondrial metabolism of acetyl CoA. Acetyl CoA acts on the acetylation status of mitochondrial proteins that increase mitochondrial transcription and protein synthesis. As a result, cytochrome B content increases with consequent increase in electron transport chain activity and stimulation of oxidative phosphorylation. Supplement should potentially restore aging related mitochondrial defect, therefore [52]. Acetyl carnitine (ALC) upregulated Hsps and expression of redox sensitive transcription factor Nrf2 following the hormetic low dose effect [53]. The evidence for modulation of mitochondrial biogenesis via transcriptional control of nuclear-respiratory factor NRF1 [54], highlight role of carnitine system in mitochondrial metabolism.

Carnitine system functions as vitagene prototype for processes of cell survival that require energy for cellular stress response and redox homeostasis [55].

Redox Biology Paradigm

As per redox biology paradigm, antioxidants primarily serve to modulate complex networks controlling cell signaling and metabolism. Central idea is that redox active mediators, eg nitric oxide, hydrogen peroxide and lipid radicals act as site specific mediators of cell signaling, protein cystein residues are the sensors or receptors of these different redox mediators AND the "traditional" antioxidants, e.g. glutathione, α -tocopherol serve the essential functions of insulating distinct redox signaling domains in the cell from cross-talk.

Dysregulation of these pathways would influence metabolism, autophagy, cell growth and repair. Most successful translational use of these pathways is of course, the selective activation of Keap1/Nrf2 system, sure to yield new drugs. Lifespan enhancing metformin effect is also dependant on oxidative stress transcription factor Nrf2 [56]. Mechanisms of hormetic triggering of endogenous cellular defense pathways include, sirtuins and Nrf2 and related pathways that integrate adaptive stress. Emerging role of nitric oxide, carbon monoxide and Hydrogen sulphide gases in hormesis based neuroprotection and their relation to radical dynamics in membrane and redox signaling is drawing particular research attention [57].

CONCLUSION AND PROSPECTS

Modern technical advances applied in aging research span across, nanotechnology, bioinformatics, single cell analysis, molecular heterogeneity analysis, analyses of epigenetic regulators of stress, analysis of post synthetic modification of biomolecules etc. Scientific gerontology, envisages rational steps to slow down aging process and rejuvenate physiological function. Redesigning of structural and functional units of body by manipulations at level of genes, gene products, macromolecular interactions, interaction with the milieu etc. are being worked upon. Their practical application in checking or reversing aging changes, is currently, far too distant.

Biochemical interactions and tradeoffs between stressor and biologic cellular responses, including pleotropic effects require thorough learning. A range of usable physical, chemical or biological stressor options with feasible technology for application must become available and must also conform to safety and efficacy standards like drugs. The task of advancing hormesis principle for practical use requires competent calibration and monitoring of magnitudes appropriate for different stressor interventions and ways to monitor them, including need for defining optimal stressor dose for given stage of aging process. Bioactive constituents from plant food have shown novel modulatory potential for transcription phenomena [58]. Since redox regulation and transcription factor cysteine modification are central to both Keap1/Nrf2/ARE pathway and the Heat shock response, such multi target agents, all of which are reactive with sulphydryl groups, are ideal for simultaneously manipulating ageing pathways to achieve synergistic benefits. Exploiting the ability of small molecules, many of them from diet and safe, to stimulate defensive stress response is highly aspired, and the ultimate objective ought be adding life to years rather than years to life [59].

Conflict of interest statement

There is no conflict of interest among the authors.

REFERENCES

1. Carnes BA, Olshansky SJ and Grahn L 2003. Biological evidence for limits to the duration of life. *Biogerontology*. 4:31-45.
2. Halliday R 1995. Understanding aging. Cambridge. Cambridge Univ, Press.
3. Gelman R, Watson A, Bronson R and Yunis E 1988. Murine chromosomal regions correlated with longevity. *Genetics*. 118:693-704.
4. Kurosu H, Yamamoto M, Clark JD, Pastor JV, Nandi A, Gurnani P et al 2005. Suppression of aging in mice by hormone Klotho. *Science*. 309:1829-1833
5. Puca AA, Daly MJ, Brewster SJ, Matsie TC, Barrett J, Shea-Drinkwater M et al. 2001. A genomewide scan for linkage to human exceptional longevity identifies a locus on chromosome 4. *PNAS*. 98:10505-10508.
6. Xu Y and Sun Z 2015. Molecular basis of klotho: from gene to function in ageing *Endocr Rev*. 36:1079
7. Kuro-O M 2008. Klotho as a regulator of oxidative stress and senescence. *Biol Chem*. 389:233-41
8. Gong Z, Tas E and Muzumdar R 2014. Humanin and age-related diseases: a new link? *Front Endocrinol (Lausanne)*. 5:210. doi: 10.3389/fendo.2014.00210
9. Kirkwood TBL 2012. Evolution of aging. *Mech Age Dev*. 123:737-745.
10. Tzanetakou IP, Katsilambros NL, Benetos A, Mikhailidis DP and Perrea DN 2012. "Is obesity linked to aging?": adipose tissue and the role of telomeres. *Ageing Res Rev*. 11:220-9
11. Yamauchi T and Kadowaki T 2013. Adiponectin receptor as a key player in healthy longevity and obesity-related diseases. *Cell Metab*. 17:185-96.
12. Ma XH, Muzumdar R, Yang XM, Gabriely I, Berger R and Barzilai N 2002. Aging is associated with resistance to effects of leptin on fat distribution and insulin action. *J Gerontol A BiolSci Med Sci*. 57:B225-31
13. Harman-Boehm I, Blüher M, Redel H, Sion-Vardy N, Ovadia S, Avinoach E et al. 2007. Macrophage infiltration into omental versus subcutaneous fat across different populations: effect of regional adiposity and the comorbidities of obesity. *J Clin Endocrinol Metab*. 92:2240-7
14. Vera E and Blasco MA 2012. Beyond average: potential for measurement of short telomeres. *Aging (Albany NY)*. 4:379-92
15. Zenquetta MM, Correa-Gionnella ML, Monteiro MB, and Villares SM 2010. Body weight, metabolism and clock genes *Diabetol. Metab. Syndr*. 2:53 doi:10.1186/1758-5996-2-53
16. Kandratov RV 2007. A role of the circadian system and circadian patterns in ageing *Ageing Research Reviews*. 6: 12-27
17. Moreno-Villanueva M and Burkle A 2014. Molecular consequences of psychological stress in human aging. *Exp Gerontol*. doi: 10.1016/j.exger.2014.12.003

18. Epel ES and Lithgow GP S 2014. Stress biology and aging mechanisms: toward understanding the deep connection between adaptation to stress and longevity. *J Gerontol A BiolSci Med Sci.* 69 Suppl 1:S10-6
19. Calabrese V Cornelius C Cuzzocrea S Iaviloli I Rizzarelli E and Calabrese EJ 2011. Hormesis, cellular stress response and vitagenes as critical determinants of ageing and longevity. *Mol Aspects Med.* 32: 279-304
20. Li J, Kim SG and Blenis J 2014. Rapamycin: one drug, many effects. *Cell Metab.* 19:373-9
21. Salminen A and Kaarniranta K 2012. AMP-activated protein kinase (AMPK) controls the aging process via an integrated signaling network. *Ageing Res Rev.* 11:230-41.
22. Dazert E and Hall MN 2011. mTOR signaling in disease. *Curr Opin Cell Biol.* 23:744-55.
23. Blagosklonny MV 2010. Calorie restriction: decelerating mTOR-driven aging from cells to organisms (including humans). *Cell Cycle.* 9:683-8
24. Kapahi P, Chen D, Rogers AN, Katewa SD, Li PW, Thomas EL and Kockel L 2010. With TOR, less is more: a key role for the conserved nutrient-sensing TOR pathway in aging. *Cell Metab.* 11:453-65
25. Conn CS and Qian SB 2013. Nutrient signaling in protein homeostasis: an increase in quantity at the expense of quality. *Sci Signal.* 6(271):ra24. doi: 10.1126/scisignal.2003520
26. Blagosklonny MV 2012. Answering the ultimate question "what is the proximal cause of aging?". *Aging (Albany NY).* 4: 861-77
27. Kaeberlein M and Kennedy BK 2011. Hot topics in aging research: protein translation and TOR signaling, 2010. *Aging Cell.* 10:185-90
28. Gallinetti J, Harputlugil E and Mitchell JR 2013. Amino acid sensing in dietary-restriction-mediated longevity: roles of signal-transducing kinases GCN2 and TOR. *Biochem J.* 449:1-10
29. Wek RC, Jiang HY and Anthony TG 2006. Coping with stress: eIF2 kinases and translational control. *Biochem Soc Trans.* 34(Pt 1):7-11
30. Spriggs KA, Bushell M and Willis AE 2010. Translational regulation of gene expression during conditions of cell stress. *Mol Cell.* 40:228-37
31. Cantó C and Auwerx J 2011. Calorie restriction: is AMPK a key sensor and effector? *Physiology (Bethesda).* 26:214-24
32. Kahn BB, Alquier T, Carling D and Hardie DG 2005. AMP-activated protein kinase: ancient energy gauge provides clues to modern understanding of metabolism. *Cell Metab.* 1:15-25.
33. Mihaylova MM and Shaw RJ 2011. The AMPK signalling pathway coordinates cell growth, autophagy and metabolism. *Nat Cell Biol.* 13:1016-23
34. Jung CH¹, Ro SH, Cao J, Otto NM and Kim DH 2010. mTOR regulation of autophagy. *FEBS Lett.* 584:1287-95
35. Kim J, Kundu M, Viollet B and Guan KL 2011. AMPK and mTOR regulate autophagy through direct phosphorylation of Ulk1. *Nat Cell Biol.* 13:132-41
36. Selman C, Tullet JM, Wieser D, Irvine E, Lingard SJ, Choudhury AI et al. 2009. Ribosomal protein S6 kinase 1 signaling regulates mammalian life span. *Science.* 326(5949):140-4.
37. Kurosu H, Yamamoto M, Clark JD, Pastor JV, Nandi A, Gurnani P et al. 2005. Suppression of aging in mice by the hormone Klotho. *Science.* 309(5742):1829-33
38. Ning J and Clemmons DR 2010. AMP-activated protein kinase inhibits IGF-I signaling and protein synthesis in vascular smooth muscle cells via stimulation of insulin receptor substrate 1 S794 and tuberous sclerosis 2 S1345 phosphorylation. *Mol Endocrinol.* 24:1218-29
39. Ruderman NB, Xu XJ, Nelson L, Cacicedo JM, Saha AK, Lan F and Ido Y 2010. AMPK and SIRT1: a long-standing partnership? *Am J PhysiolEndocrinolMetab.* 298:E751-60
40. Cantó C, Gerhart-Hines Z, Feige JN, Lagouge M, Noriega L, Milne JC et al 2009. AMPK regulates energy expenditure by modulating NAD⁺ metabolism and SIRT1 activity. *Nature.* 458(7241):1056-60
41. Salminen A, Hyttinen JM and Kaarniranta K 2011. AMP-activated protein kinase inhibits NF- κ B signaling and inflammation: impact on health span and lifespan *J Mol Med (Berl).* 89:667-76
42. Taylor RC and Dillin A 2011. Aging as an event of proteostasis collapse. *Cold Spring Harb Perspect Biol.* 1;3. pii: a004440. doi: 10.1101/cshperspect.a004440
43. Carroll B, Hewitt G and Korolchuk VI 2013. Autophagy and ageing: implications for age-related neurodegenerative diseases. *Essays Biochem.* 55:119-31
44. Anderson RM and Weindruch R 2012. The caloric restriction paradigm: implications for healthy human aging. *Am J Hum Biol.* 24:101-6
45. Barzilai N¹, Banerjee S, Hawkins M, Chen W and Rossetti L 1998. Caloric restriction reverses hepatic insulin resistance in aging rats by decreasing visceral fat. *J Clin Invest.* 101:1353-61.
46. Miron M, Verdú J, Lachance PE, Birnbaum MJ, Lasko PF and Sonenberg N 2001. The translational inhibitor 4E-BP is an effector of PI(3)K/Akt signalling and cell growth in *Drosophila*. *Nat Cell Biol.* 3:596-601.
47. Zhou G¹, Sebat IK and Zhang BB 2009. AMPK activators--potential therapeutics for metabolic and other diseases. *Acta Physiol (Oxf).* 196:175-90

48. Calabrese V¹, Cornelius C, Stella AM and Calabrese EJ 2010. Cellular stress responses, mitostress and carnitine insufficiencies as critical determinants in aging and neurodegenerative disorders: role of hormesis and vitagenes. *Neurochem Res.* 35:1880-915
49. Chen Z and Niki E 2006. 4-Hydroxynonenal (4-HNE) has been Widely Accepted as an Inducer of Oxidative Stress. Is this the Whole Truth about it or can 4-HNE also exert Protective Effects? *IUBMB Life.* 58: 372 – 373
50. Satoh T, McKercher SR and Lipton SA 2013. Nrf2/ARE-mediated antioxidant actions of pro-electrophilic drugs. *Free Radic Biol Med.* 65:645-57.
51. Mouchiroud L, Houtkooper RH, Moullan N, Katsyuba E, Ryu D, Cantó C et al 2013. The NAD(+)/Sirtuin Pathway Modulates Longevity through Activation of Mitochondrial UPR and FOXO Signaling. *Cell.* 154:430-41
52. Qu S, Zhu H, Wei X, Zhang C, Jiang L, Liu Y, Luo Q and Xiao X 2010. Oxidative stress-mediated up-regulation of myocardial ischemic preconditioning up-regulated protein 1 gene expression in H9c2 cardiomyocytes is regulated by cyclic AMP-response element binding protein. *Free Radic Biol Med.* 49:580-6
53. Noland RC¹, Koves TR, Seiler SE, Lum H, Lust RM, Ilkayeva O, et al 2009. Carnitine insufficiency caused by aging and overnutrition compromises mitochondrial performance and metabolic control. *J Biol Chem.* 284:22840-52
54. Calabrese V, Cornelius C, Dinkova-Kostova AT, and Calabrese EJ 2009. Vitagenes, cellular stress response, and acetylcarnitine: relevance to hormesis. *Biofactors.* Mar- 35:146-60
55. Piantadosi CA, Carraway MS, Babiker A and Suliman HB 2008. Heme oxygenase-1 regulates cardiac mitochondrial biogenesis via Nrf2-mediated transcriptional control of nuclear respiratory factor-1. *Circ Res.* 103:1232-40
56. Calabrese V, Mancuso C, Calvani M, Rizzarelli E, Butterfield DA and Stella AM 2007. Nitric oxide in the central nervous system: neuroprotection versus neurotoxicity. *Nat Rev Neurosci.* 8:766-75
57. Levonen AL, Hill BG, Kansanen E, Zhang J and Darley-Usmar VM 2014. Redox regulation of antioxidants, autophagy, and the response to stress: implications for electrophile therapeutics. *Free Radic Biol Med.* 71:196-207
58. Calabrese V¹, Cornelius C, Dinkova-Kostova AT, Calabrese EJ and Mattson MP 2010. Cellular stress responses, the hormesis paradigm, and vitagenes: novel targets for therapeutic intervention in neurodegenerative disorders. *Antioxid Redox Signal.* 13:1763-811.
59. Pandey G and Pandey AK 2013. Nutrition research perspectives in immune mediated inflammatory disorders. *Indian J Rheumatol.* 8:30-36.
60. Pandey AK, Pandey G, Pandey SS and Pandey BL 2014. Human biology of diet and lifestyle linked chronic inflammatory disease epidemic: a review. *Human Biol Rev.* 3:25-42.

Results of Gastroesophageal Collector Total Dissociation in Patients with Portal Hypertension

Nazyrov Firuz Gafurovich, Devyatov Andrey Vasilyevich, Babadjanov Azam Khasanovich✉ and Ruziboev Sandjar Abdusalomovich

¹Republican Specialized Centre of Surgery named after academician V.Vakhidov, Tashkent city, Uzbekistan

²Tashkent Pediatric Medical Institute, Tashkent city, Uzbekistan

✉ Corresponding author's Email: azam746@mail.ru

Received 27 Apr. 2016 • Accepted 18 Jul. 2016 • Revised 20 Sep. 2016

ABSTRACT: The purpose of research was to study long-term results of the modified technique of gastroesophageal collector total dissociation (GECTD) in patients with portal hypertension. Materials and methods. Currently a modified version of the operation has been performed in 73 patients with the portal hypertension (PH) syndrome. In 36 patients the cause of PH was liver cirrhosis, 30 patients were diagnosed with extrahepatic form of PH, mixed form of PH was determined in 8 patients. The age of patients ranged from 13 to 65 years, thus the median was 31.6 ± 1.7 years. Patients randomizing by gender was as follows: men - 44, women - 29. In 53 cases patients were admitted in a planned order, and 20 patients were delivered urgently with the clinical picture of gastroesophageal bleeding. Results and discussion remote period was followed up in 46 patients with primary procedure and in 66 patients with a modified technique of GECTD. Rebleeding was observed in 15.2% of patients, 6.5% on the background of anastomosis. Gastrostasis occurrence was detected in 3 of 46 patients. Liver failure occurred in 23.9% of patients, 15.2% patients died on the background of these complications. In the group with a modified procedure bleeding was observed in 6.0% cases. Bleedings from erosion in the area of ligature transection were stopped conservatively. Mortality in long-term period of observation was 7.6% (5 patients). Overall mortality for the near and distant periods in the comparison groups was 22.2% and 16.4%, respectively. Conclusion –dissociation of gastroesophageal venous reservoir by ligature transection on synthetic prosthesis, unlike previously proposed methods of GECTD allows not only to ease technique of operation, but also provides prevention of early postoperative complications associated with traumatism of previous methods, as well as the stomach gross functional disorders in the long term period.

Author Keywords: Liver Cirrhosis, Portal Hypertension, Dissociative Operations, Technique of Ligature Transection, Bleeding from Esophageal Varices

INTRODUCTION

Among all gastrointestinal hemorrhages from esophageal varices in patients suffering from liver cirrhosis (LC) with portal hypertension (PH) are distinguished by specific severity of clinical presentations, serious complications and high probability of lethal outcome. Without indications to radical cure of LC – liver transplantation, the basic direction of surgical treatment for such patients is of portal pool vessels reconstruction [1-3]. But there are particular indications for portosystemic shunting and it is a big patients group among those in which such intervention is impossible because of some reasons and it is required to perform another type of surgical treatment. Among mentioned portoasigos dissociation surgeries remain as a method of choice. The main advantages of them are maintenance of constant liver portal perfusion, absence of post-shunting encephalopathy and wider facilities at performing in emergency surgery of esophageal bleedings [4-6]. Besides there is strategic deficiency in emergency and planned dissociative operation types and a lack of stable late fates. So, after a year or less active restoration of varices with increasing risk of bleeding recurrence has place [7-9]. The worked-out and adopted into practice original techs of gastroesophageal collector total dissociation (GECTD) in RSCS named after acad. V.Vakhidov, have high hemostatic efficiency and are directed on elimination of known surgeries

defects. The analysis of long-term results of these surgeries with the estimation of their prophylaxis efficiency of esophageal bleedings and patients survivability presents particular interest.

Original method of GECTD with ligature transection of subcardinal part of stomach with following forming of gastrogastal collateral anastomosis has been initially worked out (such surgeries has been performed in 63 patients from 1998 to 2007). Surgery stages have included: stomach mobilization through greater stomach transaction by ligature type at the subcardinal part level; forming of gastrogastal collateral anastomosis above the ligature. Such type of surgery has two variants of performing: using ligatures or staplers. By gaining an experience we came to conclusion that a ligature type is more preferable [7, 10].

Analysis of long-term results (from 3 months to 10 years) of performed dissociative operations has been carried out in 46 patients. Rebleeding has been registered in 10.9% patients, and in 6,5% cases on the background of anastomosis. Occurrence of gastrostasis have been revealed in 5 of 46 patients. Control endoscopy 3 months after surgery has revealed stomach recanalization in the area of ligature transection with forming of two ways for food passage – recanalized natural one and through gastrogastal anastomosis. 19.6% patients died on the background of complications. Mentioned facts allowed to suppose a probability of performing ligature transection of stomach subcardinal part on wireframe base with the saving of natural way for food passage without gastrogastal anastomosis.

MATERIAL AND METHODS

GECTD modified method (F.G. Nazirov's operation) was adopted in clinical practice in 2008 [10]. Distinctive feature of new method was that dissociation is achieved because of use intraluminal prosthesis installed during the surgery.

Method is carried out as follows: approach – upper-midline laparotomy. Proximal devascularization of stomach up to esophagus abdominal part through greater and lesser curvature is carried out. Organ blood flow is saved through right gastric and two gastroepiploic arteries. The left gastric artery is ligated and transected. All short vessels of stomach are also ligated and transected (Figure 1). Then transversal gastrotomy is carried out in medium part of stomach body along anterior wall and through a formed hole synthetic prosthesis is introduced into stomach lumen and is located in the lumen of stomach subcardinal part. Above the prosthesis introduced into stomach lumen, over serous membrane ligature is put in which divides stomach to upper 1/3 and lower 2/3 parts. Ligature is tightened over the prosthesis and at the same time the prosthesis is fixed by surgeon's finger introduced into its lumen. So, the prosthesis location and ligature's tension is controlled. Then repeated ligature is put in over the first one. Corrugation of the prosthesis provides ligatures' fixation preventing their displacement (Figure 2). Nasogastric probe is passed through the prosthesis with the aim of decompression in the postoperative period. Gastrotomic hole is sutured by double-row suture. A number of sero-serous sutures are also put in over stomach ligature. Pyloroplasty is carried out additionally.

Endoscopic investigation is performed after 1-1.5 month and the prosthesis is removed out of stomach lumen. By this time put in ligatures over it are penetrated into stomach lumen and venous reservoir is dissociated.




Figure 1. Stage of stomach and esophagus abdominal part devascularization with gastrotomy.




Figure 2. Stage of ligature transection on the ring-prosthesis.

Currently operation has been performed in 73 patients with PH syndrome. In 36 patients the cause of PH was LC, in 30 patients it has been diagnosed a hepatic form of PH and in 8 cases a combined form of PH has been determined. Patients age has been varied from 13 to 65 years, thus the median was 31.6 ± 1.7 years. Patients randomizing by gender was as follows: men - 44, women – 29. In 53 cases patients were admitted in a planned order, and 20 patients were delivered urgently with the clinical picture of gastroesophageal bleeding. Patients were underwent both general (clinical and biochemical blood tests, ECG, chest X-ray) and special (liver radioisotopic investigation, angiographic) investigation methods.

The grade of esophageal varices is estimated by Shertsinger's classification [11]. The second grade of esophageal varices has been revealed in all patients. All patients had esophagogastric bleeding in anamnesis and 40 (54.8%) of them - many times. In 13 cases patients additionally have been undergone splenectomy. In 8 (11.0%) patients at admission diabetes mellitus has been revealed.

RESULTS

At the nearest postoperative period the most frequent complication of earlier worked out dissociative methods were cardiofundal anastomosis insufficiency (11.7% - at planned surgeries and 21.1% - at emergency interventions). Unlike them, an offered new method is carried out through small gastrotomic hole and such complications has not been observed. From other side in more 11.1% patients anastomosis development has been noted which significantly increased the risk of bleeding development from anastomosis zones. Hepatic failure and encephalopathy have been noted in 15 (23.8%) patients. General lethality in the nearest period made up 11.1% (7 patients).

Modified ligature transection allowed to level completely the risk of anastomosis failure and to reduce a frequency of hepatic failure and lethality (Table 1). Radiologic-contrast investigation 10 days after surgery showed that prosthesis is freely passable; stomach evacuation functions failure has not been observed. One month after surgery at control endoscopic investigation a synthetic cylinder was removed without technical difficulties. Regress of esophageal varices has been noted in all cases.

Table 1. Comparative frequency of early postoperative complications in patients with GECD by different methods

Complications	Original method	Modified method
Anastomosis failure	7 (11.1%)	--
Stomach wall necrosis in ligature transection area	2 (3.2%)	2 (2.7%)
Hepatic failure	15 (23.8%)	12 (16.4%)
Lethality	7 (11.1%)	7 (9.6%)

The analysis showed that predisposing factor to stomach wall evident ischemia development with necrosis probability in ligature area and above prosthesis is because of presence of concomitant diabetes in patients. Performing stomach devascularization with following ligature transection on the background of diabetic angiopathy significantly disturbs organ's trophics and it was a cause of necrosis. At the absence of diabetes mellitus we did not observe such type of complications. In comparative aspect the risk of stomach necrosis in the area of transection at diabetes mellitus presence increased up to 25% (in 2 from 8 patients with diabetes). This fact has influenced to technical aspects of performing dissociative operations in patients with decompensated stage of diabetes. Currently a surgery is limited only by stomach devascularization with additional ligation of left gastric vein as basic afflux to gastroesophageal venous reservoir at PH.

Remote period has been observed in 46 patients with primary procedure and in 66 patients with a modified technique of GECD. Rebleeding was observed in 15.2% of patients, and 6.5% on the background of anastomosis. Gastrostasis occurrence was detected in 3 of 46 patients. The phenomena of liver failure occurred in 23.9% of patients. 15.2% patients died on the background of these complications (Table 2). In the group with a modified procedure bleeding was observed in 6.0% cases. Two patients with bleeding from esophagus lower one third were successfully underwent sclerotherapy and there was not noted a following recurrence. Bleedings from erosion in the area of ligature transection were stopped conservatively. Mortality in long-term period of observation was 7.6% (5 patients). Overall mortality for the near and distant periods in the comparison groups was 22.2% and 16.4%, respectively.

Table 2. Comparative frequency of complications after GECTD in remote period

Complications	Original method	Modified method
Bleeding from esophageal varices	4 (8.7%)	2 (3.0%)
Bleeding from anastomosis area (anastomositis) or ligature transection	3 (6.5%)	2 (3.0%)
Gastrostasis	3 (6.5%)	1 (1.5%)
Hepatic failure	11 (23.9%)	8 (12.1%)
Mortality	7 (15.2%)	5 (7.6%)
Overall mortality in 12 months period	14 (22.2%)	12 (16.4%)

Advantages of GECTD modified method are: refusal from performing cardiofundus anastomosis – natural tract through stomach by means of prosthesis fixed in cardinal part is saved; reduction of surgery duration due to performing gastrotomy without cardiofundal anastomosis; decrease of the risk of gastrotomic hole failure development – the length of gastrotomy is 3 cm, absence of cardiofundal anastomosis; broad intramural zone of stomach cardinal part veins dissociation – external application of two ligatures above prosthesis introduced into stomach cardinal part creates the length of sclerosis up to 1 cm.

Analysis of patients survivability with LC and PH after GECTD showed that the lowest index has been revealed in the groups with large nodular cirrhotic transformation (survivability median – 24 months), in patients with bleeding in anamnesis (survivability median – 36 months) and with decompensation by edematous ascitic syndrome before operative intervention (survivability median – 12 months). Investigation has shown performing GECTD to patients with LC and high portal pressure increases the risk of hemorrhagic complications development in early and late postoperative period and respectively decreases survivability indexes till 1 year observation to 62%, 3 years – up to 47% and it is connected not only with hypertension but also with forced technical aspects of surgery (ligature transection and gastrogastro-anastomosis) on the background of portal gastropathy.

Performing GECTD to patients with LC on the background of edematic-ascitic syndrome decreases survivability indexes in the period of observation till 1 year up to 48%, 3 years – up to 43% and it is connected with progressing of two main factors in remote period – portal hypertension and increasing hepatic failure with functional decompensation of hepatocytes.

GECTD in patients without vascular and edematic-ascitic decompensation of LC with PH increases survivability indexes in the period of observation till 1 year up to 87%, 3 years – up to 67% and 5 years up to 58%. In other cases on the background of progressing above mentioned complications, it is reasonable to perform different types of intersystem vascular bypass as basic type of intervention directed to portal system decompression.

CONCLUSIONS

Dissociation of gastroesophageal venous reservoir by ligature transection on synthetic prosthesis previously implanted in stomach unlike previously proposed methods of GECTD allows not only to ease the technique of operation, but also provides prevention of early postoperative complications associated with traumatism of previous methods, as well as the stomach gross functional disorders in the long term period.

Advanced original tech of GECTD is the most perspective operative method in emergency surgery and in planned operative interventions in patients with PH syndrome undergone repeated operative treatment or it can be alternative to portosystemic shunting method, at impossibility of performing the last one. Our investigation shows that described technique had showed it reliability and efficiency.

Acknowledgements

This work was supported by Republican Specialized Centre of Surgery, Tashkent City, Uzbekistan.

Competing interests

The authors declare that they have no competing interests.

REFERENCES

1. Elkrief L, Rautou PE, Ronot V, Lambert S, Dioguardi Burgio M, Francoz C, Plessier A, Durand F, Valla D, Lebre D, Vilgrain V, Castéra L. 2014. Prospective Comparison of Spleen and Liver Stiffness by Using Shear-Wave and Transient Elastography for Detection of Portal Hypertension in Cirrhosis. *Radiology*. 28: 141210-14.

2. Fung J, Lai CL, Yuen MF. 2014. Management of chronic hepatitis B in severe liver disease. *World J Gastroenterol.* 20(43): 16053-61.
3. Tandon P, Abraldes JG, Keough A, Bastiampillai R, Jayakumar S, Carbonneau M, Wong E, Kao D, Bain VG, Ma M. 2014. Risk of Bacterial Infection in Patients with Cirrhosis and Acute Variceal Hemorrhage, Based on Child-Pugh Class, and Effects of Antibiotics. *Clin Gastroenterol Hepatol.* S1542: P. 3565-69
4. Biyik M, Ucar R, Cifci S, Ozbek S, Gungor G, Ozer Cakir O, Yavuz F, Ataseven F, Demir A. 2014. External hemorrhage from a portacaval anastomosis in a patient with liver cirrhosis. *Case Reports Hepatol.* 5: 523610-13.
5. Cárdenas A, Baiges A, Hernandez-Gea V, Garcia-Pagan JC. 2014. Endoscopic Hemostasis in Acute Esophageal Variceal Bleeding. *Gastroenterol Clin North Am.* 43(4): 795-806.
6. Stefanescu H, Procopet B. 2014. Noninvasive assessment of portal hypertension in cirrhosis: Liver stiffness and beyond. *World J Gastroenterol.* 20 (45): 16811-19.
7. Devyatov AV, Mansurov AA, Hashimov ShH, Nijazmetov AN, Hafizov BB. 2002. Variations of technical excellence in dissociative surgical tactics in patients with portal hypertension. *Uzbekistan Surgery*, 1: 19-22. [Article in Russian: Девятков А.В. Варианты технического совершенствования разобщающих операций у больных с портальной гипертензией. А.В. Девятков, А.А. Мансуров, Ш.Х. Хашимов, А.Н. Ниязметов, Б.Б. Хафизов. Хирургия Узбекистана. – 2002. - №1.- С.19-22.]
8. Eramishancev AK, Kicenko EA, Nechaenko AM, Grigorjan RS. 2002. Treatment strategies in patients with subliver portal hypertension after Paciora procedure. *Annals of surgical hepatology.* 1: 27-32. [Article in Russian: Ерамишанцев А.К. Тактика ведения больных с внепеченочной портальной гипертензией после прошивания варикозно расширенных вен пищевода и желудка. А.К. Ерамишанцев, Е.А. Киценко, А.М. Нечаенко, Р.С. Григорян. Анналы хирургической гепатологии. - 2002. - Том 10. - №1. - С. 27-32.]
9. Mansurov AA. Tactical aspects and new technologies of dissociative and reconstructive bypass surgery in patients with portal hypertension. 2004. MD dissertation. Tashkent. p 115 [Article in Russian: Тактические аспекты и новые технологии разобщающих и реконструктивных шунтирующих операций у больных с портальной гипертензией. Мансуров А.А. Автореферат дисс. докт.мед.наук. – Ташкент. – 2004. – 115 с.]
10. Nazyrov FG, Jamilov JD, Devyatov AV, Babajanov AKh. 2015. *Journal of Modern Clinical Medicine.* Moscow. 3(8): 33.
11. Sherzinger A. 1986. Pathogenesis, diagnostics, prophylactics and treatment of gastroesophageal bleeding in patients with portal hypertension. Annotation of MD dissertation. Moscow P. 38с. [In Russian: Шерцингер А.Г. Патогенез, диагностика, профилактика, лечение кровотечений из варикозных вен пищевода и желудка у больных портальной гипертензией. // Автореферат дисс. докт. мед. наук. М., 1986. 38с].

Instructions for Authors

Manuscript as Original Research Paper, Review and Case Reports are invited for rapid peer-review publishing in the *Journal of Life Science and Biomedicine*. Considered subject areas include: Biocontrol, Biochemistry, Biotechnology, Bioengineering, Neurobiology... [view full aims and scope](#)

[JLSB EndNote Style](#)

[Manuscript Template \(.doc\)](#)

[Sample Articles](#)

[Declaration form](#)

[Policies and Publication Ethics](#)

Submission

The manuscript and other correspondence should preferentially be [submit online](#). Please embed all figures and tables in the manuscript to become one single file for submission. Once submission is complete, the system will generate a manuscript ID and will send an email regarding your submission. Meanwhile, the authors can submit or track articles via editors@jlsb.science-line.com ; jlsb.editors@gmail.com. All manuscripts must be checked (by English native speaker) and submitted in English for evaluation (in totally confidential and impartial way).

Supplementary information

The online submission form allows supplementary information to be submitted together with the main manuscript file and covering letter. If you have more than one supplementary files, you can submit the extra ones by email after the initial [submission](#). Author guidelines are specific for each journal. Our Word template can assist you by modifying your page layout, text formatting, headings, title page, image placement, and citations/references such that they agree with the guidelines of journal. If you believe your article is fully edited per journal style, please use our [MS Word template](#) before submission. **Supplementary materials** may include figures, tables, methods, videos, and other materials. They are available online linked to the original published article. Supplementary tables and figures should be labeled with a "S", e.g. "Table S1" and "Figure S1". The maximum file size for supplementary materials is 10MB each. Please keep the files as small possible to avoid the frustrations experienced by readers with downloading large files.

Submission to the Journal is on the understanding that

- 1.The article has not been previously published in any other form and is not under consideration for publication elsewhere;
- 2.All authors have approved the submission and have obtained permission for publish work.
- 3.Researchers have proper regard for conservation and animal welfare considerations. Attention is drawn to the '[Guidelines for the Treatment of Animals in Research and Teaching](#)'. Any possible adverse consequences of the work for populations or individual organisms must be weighed against the possible gains in knowledge and its practical applications. If the approval of an ethics committee is required, please provide the name of the committee and the approval number obtained.

Ethics Committee Approval


Experimental research involving human or animals should have been approved by author's institutional review board or ethics committee. This information can be mentioned in the manuscript including the name of the board/committee that gave the approval. Investigations involving humans will have been performed in accordance with the principles of [Declaration of Helsinki](#). And the use of animals in experiments will have observed the *Interdisciplinary Principles and Guidelines for the Use of Animals in Research, Testing, and Education* by the New York Academy of Sciences, Ad Hoc Animal Research Committee. If the manuscript contains photos or parts of photos of patients, informed consent from each patient should be obtained. Patient's identities and privacy should be carefully protected in the manuscript.

Graphical Abstract

Authors should provide a graphical abstract (a beautifully designed feature figure) to represent the paper aiming to catch the attention and interest of readers. Graphical abstract will be published online in the table of content. The graphical abstract should be colored, and kept within an area of 12 cm (width) x 6 cm (height) or with similar format. Image should have a minimum resolution of 300 dpi and line art 1200dpi.

Note: Height of the image should be no more than the width.

Please avoid putting too much information into the graphical abstract as it occupies only a small space. Authors can provide the graphical abstract in the format of PDF, Word, PowerPoint, jpg, or png, after a manuscript is accepted for publication. For preparing a Professional Graphical Abstract, please click [here](#).



Presentation of the article

Main Format

First page of the manuscripts must be properly identified by the title and the name(s) of the author(s). It should be typed in Times New Roman (font sizes: 17pt in capitalization for the title, 10pt for the section headings in the body of the text and the main text, double spaced, in A4 format with 2cm margins (both doc./docx formats). All pages and lines of the main text should be numbered consecutively throughout the manuscript. Abbreviations in the article title are not allowed. Manuscripts should be arranged in the following order:

1. **TITLE** (brief, attractive and targeted)
2. **Name(s) and Affiliation(s) of author(s)** (including post code and corresponding Email)
3. **ABSTRACT**
4. **Key words** (separate by semicolons; or comma,)
5. **Abbreviations** (those used throughout the manuscript)
6. **INTRODUCTION** (clear statement of the problem, the relevant literature on the subject, and the proposed approach or solution)
7. **MATERIAL AND METHOD** (should be complete enough to allow experiments to be reproduced)
8. **RESULTS**
9. **DISCUSSION**
10. **CONCLUSION**
11. **DECLARATIONS** (Acknowledgements, Consent to publish, Competing interests, Authors' contributions, and Availability of data etc.)
12. **REFERENCES**
13. **Tables**
14. **Figures**
15. **Graphs**

Results and Discussion can be presented jointly.

Discussion and Conclusion can be presented jointly.

Article Sections Format

Title should be a brief phrase describing the contents of the paper. The first letter of each word in title should use upper case. The Title Page should include the author(s)'s full names and affiliations, the name of the corresponding author along with phone and e-mail information. Present address (es) of author(s) should appear as a footnote.

Abstract should be informative and completely self-explanatory, briefly present the topic, state the scope of the experiments, indicate significant data, and point out major findings and conclusions. The abstract should be 150 to 300 words in length. Complete sentences, active verbs, and the third person should be used, and the abstract should be written in the past tense. Standard nomenclature should be used and abbreviations should be avoided. No literature should be cited.

Following the abstract, about 3 to 8 **key words** that will provide indexing references should be listed.

Introduction should provide a clear statement of the problem, the relevant literature on the subject, and the proposed approach or solution. It should be understandable to colleagues from a broad range of scientific disciplines.

Material and Method should be complete enough to allow experiments to be reproduced. However, only truly new procedures should be described in detail; previously published procedures should be cited, and important modifications of published procedures should be mentioned briefly. Capitalize trade names and include the manufacturer's name and address. Subheadings should be used. Methods in general use need not be described in detail. The **ethical approval** for using human and animals in the researches should be indicated in this section with a separated title.

Results should be presented with clarity and precision. The results should be written in the past tense when describing findings in the author(s)'s experiments. Previously published findings should be written in the present tense. Results should be explained, but largely without referring to the literature. In case of the effectiveness of a particular drug or other substances as inhibitor in biological or biochemical processes, the results should be provided as **IC₅₀** (**half maximal inhibitory concentration**) or similar appropriate manner.

Discussion should interpret the findings in view of the results obtained in this and in past studies on this topic. State the conclusions in a few sentences at the end of the paper. The Results and Discussion sections can include subheadings, and when appropriate, both sections can be combined.

Conclusion should be brief and tight about the importance of the work or suggest the potential applications and extensions. This section should not be similar to the Abstract content.

Declarations including Acknowledgements, Author contribution, Competing interests, Consent to publish, and Availability of data etc.

Tables should be kept to a minimum and be designed to be as simple as possible. Tables are to be typed double-spaced throughout, including headings and footnotes. Each table should be on a separate page, numbered consecutively in Arabic numerals and supplied with a heading and a legend. Tables should be self-explanatory without reference to the text. The details of the methods used in the experiments should preferably be described in the legend instead of in the text. The same data should not be presented in both table and graph forms or repeated in the text.

Figure legends should be typed in numerical order on a separate sheet. Graphics should be prepared using applications capable of generating high resolution GIF, TIFF, JPEG or PowerPoint before pasting in the Microsoft Word manuscript file. Use Arabic numerals to designate figures and upper case letters for their parts (Figure 1). Begin each legend with a title and include sufficient description so that the figure is understandable without reading the text of the manuscript. Information given in legends should not be repeated in the text.

Declarations

Please ensure that the sections: Ethics (and consent to participate, if any), Acknowledgements, Author contribution, Competing interests, Consent to publish, Availability of data and materials are included at the end of your manuscript in a Declarations section.

Acknowledgements

We encourage authors to include an Acknowledgements section. Please acknowledge anyone who contributed towards the study by making substantial contributions to conception, design, acquisition of data, or analysis and interpretation of data, or who was involved in drafting the manuscript or revising it critically for important intellectual content, but who does not meet the criteria for authorship. Please also include their source(s) of funding. Please also acknowledge anyone who contributed materials essential for the study. Authors should obtain permission to acknowledge from all those mentioned in the Acknowledgements. Please list the source(s) of funding for the study, for each author, and for the manuscript preparation in the acknowledgements section. Authors must describe the role of the funding body, if any, in study design; in the collection, analysis, and interpretation of data; in the writing of the manuscript; and in the decision to submit the manuscript for publication.

Author contribution

For manuscripts with more than one author, JLSB require an Author Contributions section to be placed after the Acknowledgements section. An 'author' is generally considered to be someone who has made substantive intellectual contributions to a published study. To qualify as an author one should 1) have made substantial contributions to conception and design, or acquisition of data, or analysis and interpretation of data; 2) have been involved in drafting the manuscript or revising it critically for important intellectual content; and 3) have given final approval of the version to be published. Each author should have participated sufficiently in the work to take public responsibility for appropriate portions of the content. Acquisition of funding, collection of data, or general supervision of the research group, alone, does not justify authorship. **We suggest the following format/example** (please use initials to refer to each author's contribution): AB carried out the molecular genetic studies, participated in the sequence alignment and drafted the manuscript. JY carried out the immunoassays. MT participated in the sequence alignment. ES participated in the design of the study and performed the statistical analysis. FG conceived of the study, and participated in its design and coordination and helped to draft the manuscript. All authors read and approved the manuscript. For authors that equally participated in a study please write 'All/Both authors contributed equally to this work.' Contributors who do not meet the criteria for authorship should be listed in an acknowledgements section.

Competing interests

Competing interests that might interfere with the objective presentation of the research findings contained in the manuscript should be declared in a paragraph heading "Competing interests" (after Acknowledgment or Author Contribution sections). Examples of competing interests are ownership of stock in a company, commercial grants, board membership, etc. If there is no competing interest, please use the statement "The authors declare that they have no competing interests.". *Journal of Life Science and Biomedicine* adheres to the definition of authorship set up by [The International Committee of Medical Journal Editors \(ICMJE\)](#). According to the ICMJE authorship criteria should be based on 1) substantial contributions to conception and design of, or acquisition of data or analysis and interpretation of data, 2) drafting the article or revising it critically for important intellectual content and 3) final approval of the version to be published. Authors should meet conditions 1, 2 and 3. It is a requirement that all authors have been accredited as appropriate upon submission of the manuscript. Contributors who do not qualify as authors should be mentioned under Acknowledgements.

Consent to publish

Please include a 'Consent for publication section in your manuscript. If your manuscript contains any individual person's data in any form (including individual details, images or videos), consent to publish must be obtained from that person, or in the case of children, their parent or legal guardian. All presentations of case reports must have consent to publish. You can use your institutional consent form or our consent form if you prefer. You should not send the form to us on submission, but we may request to see a copy at any stage (including after publication). If your manuscript does not contain any individual persons data, please state "Not applicable" in this section.

Change in authorship

We do not allow any change in authorship after provisional acceptance. We cannot allow any addition, deletion or change in sequence of author name. We have this policy to prevent the fraud.

Data deposition

Nucleic acid sequences, protein sequences, and atomic coordinates should be deposited in an appropriate database in time for the accession number to be included in the published article. In computational studies where the sequence information is unacceptable for inclusion in databases because of lack of experimental validation, the sequences must be published as an additional file with the article.

REFERENCES

A JLSB reference style for [EndNote](#) may be found [here](#). However, we prefer [Vancouver](#) referencing style that is often used in medicine and the natural sciences. Uniform requirements for manuscripts submitted to Biomedical Journals, published by International Committee of Medical Journal Editors, includes a list with examples of references https://www.nlm.nih.gov/bsd/uniform_requirements.html in the *Vancouver* style.

References should be numbered consecutively and cited in the text by number in square brackets [1, 2] instead of parentheses (and not by author and date). References should not be formatted as footnotes. Avoid putting personal communications and unpublished observations as references. All the cited papers in the text must be listed in References. All the papers in References must be cited in the text. Where available, URLs for the references should be provided.

Examples (at the text, blue highlighted)

Smit [1] ...; Smit and Janak [2]...; Nurai et al. [3] reported that ; ... [1], --- [2, 3], --- [3-7]. The references at the end of this document are in the preferred referencing style. Give all authors' names; do not use "et al." unless there are six authors or more. Use a space after authors' initials. Papers that have not been published should be cited as "unpublished". Papers that have been accepted for publication, but not yet specified for an issue should be cited as "to be published". Papers that have been submitted for publication should be cited as "submitted for publication". Capitalize only the first word in a paper title, except for proper nouns and element symbols. For papers published in translation journals, please give the English citation first, followed by the original foreign-language citation.

Acceptable Examples (at References section)

For Journals:

1. Hasan V, Sri Widodo M and Semedi B. 2015. Oocyte diameter distribution and fecundity of Javaen Barb (*Systomus Orphoides*) at the start of rainy season in Lenteng River, East Java, Indonesia insurance. J. Life Sci Biomed, 5(2): 39-42.
2. Karen KS, Otto CM. 2007. Pregnancy in women with valvular heart disease. Heart. 2007 May; 93(5): 552-558.
3. Doll MA, Salazar-González RA, Bodduluri S, Hein DW. Arylamine N-acetyltransferase 2 genotype-dependent N-acetylation of isoniazid in cryopreserved human hepatocytes. Acta Pharm Sin B, 2017; 7(4):517-522.

For In press manuscripts (maximum 2):

Hasan V, Sri Widodo M and Semedi B. 2015. Oocyte Diameter Distribution and Fecundity of Javaen Barb (*Systomus Orphoides*) at the Start of Rainy Season in Lenteng River, East Java, Indonesia insurance. In press.

For symposia reports and abstracts:

Cruz EM, Almatar S, Aludul EK and Al-Yaqout A. 2000. Preliminary Studies on the Performance and Feeding Behaviour of Silver Pomfret (*Pampus argentens euphrasen*) Fingerlings fed with Commercial Feed and Reared in Fibreglass Tanks. Asian Fisheries Society Manila, Philippine 13: 191-199.

For Conference:

Skinner J, Fleener B and Rinchiuso M. 2003. Examining the Relationship between Supervisors and Subordinate Feeling of Empowerment with LMX as A Possible Moderator. 24th Annual Conference for Industrial Organizational Behavior.

For Book:

Russell, Findlay E, 1983. Snake Venom Poisoning, 163, Great Neck, NY: Scholium International. ISBN 0-87936-015-1.

For Web Site:

Bhatti SA and Firkins JT. 2008. http://www.ohioline.osu.edu/sc1156_27.html.

Nomenclature and Abbreviations

Nomenclature should follow that given in NCBI web page and Chemical Abstracts. Standard abbreviations are preferable. If a new abbreviation is used, it should be defined at its first usage. Abbreviations should be presented in one paragraph, in the format: "term: definition". Please separate the items by " ;".

E.g. ANN: artificial neural network; CFS: closed form solution; ...

Abbreviations of units should conform with those shown below:

Decilitre	dl	Kilogram	kg
Milligram	mg	hours	h
Micrometer	mm	Minutes	min
Molar	mol/L	Mililitre	ml
Percent	%	.	

Other abbreviations and symbols should follow the recommendations on units, symbols and abbreviations: in "A guide for Biological and Medical Editors and Authors (the Royal Society of Medicine London 1977). Papers that have not been published should be cited as "unpublished". Papers that have been accepted for publication, but not yet specified for an issue should be cited as "to be published". Papers that have been submitted for publication should be cited as "submitted for publication".

Formulae, numbers and symbols

1. Typewritten formulae are preferred. Subscripts and superscripts are important. Check disparities between zero (0) and the letter O, and between one (1) and the letter I.
2. Describe all symbols immediately after the equation in which they are first used.
3. For simple fractions, use the solidus (/), e.g. 10 /38.
4. Equations should be presented into parentheses on the right-hand side, in tandem.
5. Levels of statistical significance which can be used without further explanations are *P < 0.05, **P < 0.01, and ***P < 0.001.
6. In the English articles, a decimal point should be used instead of a decimal comma.
7. Use Symbol fonts for "±"; "≤" and "≥" (avoid underline).
8. In chemical formulae, valence of ions should be given, e.g. Ca²⁺ and CO₃²⁻, not as Ca⁺⁺ or CO₃.
9. Numbers up to 10 should be written in the text by words. Numbers above 1000 are recommended to be given as 10 powered x.
10. Greek letters should be explained in the margins with their names as follows: Αα - alpha, Ββ - beta, Γγ - gamma, Δδ - delta, Εε - epsilon, Ζζ - zeta, Ηη - eta, Θθ - theta, Ιι - iota, Κκ - kappa, Λλ - lambda, Μμ - mu, Νν - nu, Ξξ - xi, Οο - omicron, Ππ - pi, Ρρ - rho, Σσ - sigma, Ττ - tau, Υυ - ipsilon, Φφ - phi, Χχ - chi, Ψψ - psi, Ωω - omega. Please avoid using math equations in Word whenever possible, as they have to be replaced by images in xml full text.

Review/Decisions/Processing/Policy

Firstly, all manuscripts will be checked by [Docol@c](#), a plagiarism finding tool. The received papers with plagiarism rate of more than 30% will be rejected. Manuscripts that are judged to be of insufficient quality or unlikely to be competitive enough for publication will be returned to the authors at the initial stage. The remaining manuscripts go through a single-blind review process by external reviewers selected by section editor of JLSB, who are research workers specializing in the relevant field of study. One unfavourable review means that the paper will not be published and possible decisions are: accept as is, minor revision, major revision, or reject. The corresponding authors should submit back their revisions within 14 days in the case of minor revision, or 30 days in the case of major revision. Manuscripts with significant results are typically published at the highest priority. The editor who received the final revisions from the corresponding authors shall not be hold responsible for any mistakes shown in the final publication.

The submissions will be processed free of charge for invited authors, authors of hot papers, and corresponding authors who are editorial board members of the *Journal of Life Science and Biomedicine*. This journal encourage the academic institutions in low-income countries to publish high quality scientific results, free of charges.

Plagiarism

Manuscripts are screened for plagiarism by [Docol@c](#), before or during publication, and if found (more than 30% duplication limit) they will be rejected at any stage of processing. If we discovered accidental duplicates of published article(s) that are determined to violate our journal publishing ethics guidelines (such as multiple submission, bogus claims of authorship, plagiarism, fraudulent use of data or the like), the article will be "Withdrawn" from SCIENCELINE database. Withdrawn means that the article content (HTML and PDF) is removed and replaced with a HTML page and PDF simply stating that the article has been withdrawn according to the [Scienceline Policy](#) on Published Article Withdrawal.

Date of issue

All accepted articles are published bimonthly around 25th of January, March, May, July, September and November, each year in full text on the internet.

The OA policy

Journal of Life Science and Biomedicine is an open access journal which means that all content is freely available without charge to the user or his/her institution. Users are allowed to read, download, copy, distribute, print, search, or link to the full texts of the articles, or use them for any other lawful purpose, without asking prior permission from the publisher or the author. This is in accordance with the [BOAI definition of Open Access](#).

Submission Preparation Checklist

- Authors are required to check off their submission's compliance with all of the following items, and submissions may be returned to authors that do not adhere to the following guidelines.
- The submission has not been previously published, nor is it before another journal for consideration (or an explanation has been provided in Comments to the Editor).
- The submission file is in Microsoft Word, RTF, or PDF document file format. Where available, URLs for the references have been provided.
- The text is single-spaced; uses a 12-point font; and all illustrations, figures, and tables are placed within the text at the appropriate points, rather than at the end. The text adheres to the stylistic and bibliographic requirements outlined in the Author Guidelines.

Paper Submission Flow



SCIENCELINE PUBLISHING CORPORATION


Scienceline Publication Ltd is a limited liability non-profit non-stock corporation incorporated in Turkey, and also is registered in Iran. Scienceline journals that concurrently belong to many societies, universities and research institutes, publishes internationally peer-reviewed open access articles and believe in sharing of new scientific knowledge and vital research in the fields of life and natural sciences, animal sciences, engineering, art, linguistic, management, social and economic sciences all over the world. Scienceline journals include:

Online Journal of Animal and Feed Research



ISSN 2228-7701; Bi-monthly
[View Journal](#) | [Editorial Board](#)
 Email: editors@ojaf.ir
[Submit Online >>](#)

Journal of Civil Engineering and Urbanism




ISSN 2252-0430; Bi-monthly
[View Journal](#) | [Editorial Board](#)
 Email: ojceu@ojceu.ir
[Submit Online >>](#)

Journal of Life Sciences and Biomedicine




ISSN: 2251-9939; Bi-monthly
[View Journal](#) | [Editorial Board](#)
 Email: editors@jlsb.science-line.com
[Submit Online >>](#)

Asian Journal of Medical and Pharmaceutical Researches



ISSN: 2322-4789; Quarterly
[View Journal](#) | [Editorial Board](#)
 Email: editor@ajmpr.science-line.com
[Submit Online >>](#)

Journal of World's Poultry Research



ISSN: 2322-455X; Quarterly
[View Journal](#) | [Editorial Board](#)
 Email: editor@jwpr.science-line.com
[Submit Online >>](#)

World's Veterinary Journal




ISSN: 2322-4568; Quarterly
[View Journal](#) | [Editorial Board](#)
 Email: editor@wjv.science-line.com
[Submit Online >>](#)

Journal of Educational and Management Studies




ISSN: 2322-4770; Quarterly
[View Journal](#) | [Editorial Board](#)
 Email: info@jems.science-line.com
[Submit Online >>](#)

Journal of World's Electrical Engineering and Technology



ISSN: 2322-5114; Irregular
[View Journal](#) | [Editorial Board](#)
 Email: editor@jweet.science-line.com
[Submit Online >>](#)

Journal of Art and Architecture Studies



ISSN: 2383-1553; Irregular
[View Journal](#) | [Editorial Board](#)
 Email: jaas@science-line.com
[Submit Online >>](#)

Asian Journal of Social and Economic Sciences



ISSN: 2383-0948; Quarterly
[View Journal](#) | [Editorial Board](#)
 Email: ajses@science-line.com
[Submit Online >>](#)

Journal of Applied Business and Finance Researches



ISSN: 2382-9907; Quarterly
[View Journal](#) | [Editorial Board](#)
 Email: jabfr@science-line.com
[Submit Online >>](#)

Scientific Journal of Mechanical and Industrial Engineering



ISSN: 2383-0980; Quarterly
[View Journal](#) | [Editorial Board](#)
 Email: sjmie@science-line.com
[Submit Online >>](#)